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ABSTRACT OF DISSERTATION

THE RADIOSENSITIZATION EFFECT OF PARTHENOLIDE IN PROSTATE
CANCER: IMPLICATIONS FOR SELECTIVE CANCER KILLING BY
MODULATION OF INTRACELLULAR REDOX STATE
Parthenolide (PN), a major active component of the traditional herbal medicine
feverfew, has been shown to have anti-inflammatory and anti-tumor properties. More
remarkably, the cytotoxicity of PN seems selective to tumor cells but not their normal
cell counterparts. In the present study, we investigate whether and how PN selectively
enhances tumor sensitivity to radiation therapy by using prostate cancer cells LNCaP,
DU145 and PC3, as well as normal prostate epithelial cells PrEC.
Our study demonstrates that inhibition of NF-κB pathway and suppression of its
downstream target MnSOD are common mechanisms for the radiosensitization effect of
PN in prostate cancer cells. The differential susceptibility to PN in two radioresistant
cancer cells, DU145 and PC3, is due, in part, to the fact that in addition to NF-κB
inhibition, PN activates the PI3K/Akt pro-survival pathway in both cell lines. The
presence of PTEN in DU145 cells enhances the radiosensitization effect of PN by
suppression of the steady state level of activated p-Akt.
We also demonstrate that PN selectively exhibits a radiosensitization effect on
prostate cancer PC3 cells but not on normal prostate epithelial PrEC cells. PN causes
oxidative stress in PC3 cells but not in PrEC cells, as determined by the oxidation of the
ROS-sensitive probe H2DCFDA and intracellular reduced thiol and disulfide levels. In
PC3 but not PrEC cells, PN activates NADPH oxidase leading to a decrease in the level
of reduced thioredoxin, activation of PI3K/Akt and consequent FOXO3a phosphorylation,
which results in the downregulation of FOXO3a targets, antioxidant enzyme MnSOD and
catalase. Importantly, when combined with radiation, PN further increases ROS levels in
PC3 cells, while it decreases radiation-induced oxidative stress in PrEC cells, possibly by
increasing GSH level.
Overall, our data support the concept that increasing oxidative stress in cancer cells,
which are already under high constitutive oxidative stress, will lead to cell death, while
the same stress may allow normal cells to maintain redox homeostasis through adaptive

response. Thus, modulating cell redox status may be a novel approach to efficiently and
selectively kill cancer cells.
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Chapter One
Introduction

Prostate cancer has a high incidence in the United States. It is estimated that about
one man in six will be diagnosed with prostate cancer during his lifetime. It accounted for
about one-fourth of newly diagnosed cancer cases and causes 10% of cancer deaths in
men in 2008 [1]. The treatment of prostate cancer commonly involves surgery, radiation,
and hormone therapy. Radiation can be used to treat patients with any stage of prostate
cancer. Patients with localized early-stage prostate cancer can be effectively treated with
radiation, which is also used after surgery to destroy the cancer cells that may remain in
the original area, and thus preventing cancer recurrence. For the advanced stage of
prostate cancer, radiation treatment may be used to reduce the tumor size and help relieve
pain. However, according to a multi-institutional pooled study, in patients with
pretreatment PSA levels of 10-20, 20-30 and more than 30 ng/ml, the 5-year biochemical
recurrence free rates (no evidence of disease on the basis of the PSA value) were 68%,
51%, and 31%, respectively [2]. One possibility for the recurrence of prostate cancer after
radiation treatment is that cancer cells develop radioresistance. Therefore, finding agents
that sensitize prostate tumor cells to radiation therapy would enhance tumor response and
possibly prevent tumor recurrence.

Radiation therapy
Radiation therapy works mostly by the generation of free radicals. Ionizing radiation,
such as X-ray and gamma ray, ejects electrons from atoms when they are absorbed by
biological material. The loss and gain of electrons generate free radicals. The free
radicals initially formed in the presence of O2 may include hydroxyl radical (OH·),
superoxide (O2-·), and organic radicals (R·) [3] (Figure 1.1). The reactions of these free
radicals generate more reactive species, such as hydrogen peroxide (H2O2) and organic
hydroperoxide (ROOH). The biological effect of ionizing radiation may be due to direct
action and indirect action [4]. Direct action refers to that radiation directly ionizes the
atoms of some critical targets in the cells, such as DNA, leading to the damage of DNA.
Alternatively, radiation can ionize other molecules, especially water, which constitutes
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about 80% of cell content, to produce free radicals, such as hydroxyl radical OH·(Figure
1.1). The free radicals can then diffuse to damage the DNA, protein and lipid targets.
This is called indirect action, which is dominant for ionizing radiation. The damaging
effect of radiation is greatly enhanced if O2 is present during radiation, which is called the
oxygen effect. One possible mechanism for the oxygen effect is that, in the presence of
oxygen, the radical formed in the biological targets (R·) can react with oxygen to form
organic hydroperoxide (RO2·), which cannot be regenerated to the original compound (R)
and is considered irreparable, thus “fixing” the damage [4]. Another possibility is that
superoxide radical (O2-·), which is formed in the presence of oxygen during radiation,
contributes to the oxygen effect. This is supported by the fact that higher superoxide
dismutase (SOD) activity reduces the oxygen enhancement ratio [5]. Since using a free
radical scavenger can reduce the effect of ionizing radiation by a factor of three, it is
estimated that about two-thirds of the biological damage by radiation is due to the free
radical mediated mechanism [4].
In addition to the free radicals generated immediately after radiation by direct
ionization, radiation also induces reactive species production by other sources. Leach et
al. showed that radiation-induced ROS/RNS (Reactive oxygen species/ Reactive nitrogen
species) generation within 10 minutes after radiation is inhibited by mitochondrial
permeability transition inhibitor cyclosporin A, and is absent in the mitochondriadeficient ρo cells [6], indicating that mitochondria are important source for radiationinduced reactive species. Nitric oxide synthase is also activated several minutes after
radiation treatment, leading to the generation of nitric oxide (NO·) [7]. NADPH oxidase
is shown to be involved in radiation-induced ROS generation at a later time point (up to
12 hours) [8]. The free radicals generated from different sources after radiation may act
later at different time points and amplify or prolong the deleterious effect of radiation,
leading to cell death, the bystander effect [9], chronic oxidative stress and normal tissue
injury [10].
The major biological target of X-ray is DNA. Radiation induces diverse types of
DNA lesions including both base modifications and strand breaks, mainly through the
free radical-mediated mechanism. Double-stranded breaks are regarded as the most lethal
lesions. Unrepaired DNA lesions lead to genetic instability and increased frequency of
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mutations and chromosomal aberrations. Lethal mutations or dysfunctional chromosomal
aberrations eventually lead to the loss of replicative potential, usually after several
mitotic cycles. This is called the mitotic cell death pathway, which is the predominant
mechanism by which radiation kills mammalian cells. The oxidative DNA damage
caused by radiation also triggers apoptotic cell death, which is usually p53 dependent.
However, apoptosis is not the major form of cell death in irradiated solid tumors,
including prostate tumors [11].
In addition to oxidative damage to DNA, the reactive species generated by radiation
can also activate multiple intracellular signaling pathways involved in the control of cell
death and survival, leading to either apoptotic and cell death response, or adaptive and
repair response. For example, radiation can alter cytoplasmic Ca2+ homeostasis [12] or
act on the cellular membrane to induce ceramide production [13], leading to apoptosis.
Radiation-induced mitochondria damage [14] and the activation of Fas, TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand) and TNF-α (tumor necrosis factor
alpha) death receptor pathways also contribute to radiation-induced cell death [15]. In
addition to the induction of cell death pathways, X-ray has also been shown to activate a
number of pathways and transcription factors involved in cell cycle arrest, DNA damage
repair, anti-apoptosis and cell growth such as ATM (ataxia telangiectasia mutated), p53,
EGFR (epidermal growth factor receptor), PI3K (phosphatidylinositol 3-kinase)/AKT,
MAPK (mitogen activated protein kinase), and NF-κB (nuclear factor kappa B) [16]. The
induction of DNA damage repair and reactive species detoxification processes by
radiation has been implicated in radioadaptive response [17, 18] and may also contribute
to induced resistance to radiation.

Radioresistance
The mechanisms for the development of radiation resistance in human tumor are not
yet fully understood. Mutation or constitutive activation of some prosurvival pathways
has been correlated with resistance to X-ray-induced cell killing [19]. A proteomics study
performed by Skvortsova and colleagues has shown that radiation resistant prostate
cancer cells [20] exhibit higher levels of androgen receptor and epidermal growth factor
receptor (EGFR) and activation of their downstream pathways, such as the Ras-mitogen-
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activated protein kinase (MAPK) and phosphatidyl inositol 3-kinase (PI3K)-Akt and JakSTAT pathways. Activation of NF-κB pathway has also been associated with the
development of radioresistance in prostate cancer cells [21].
Since radiation mainly kills cells by inducing oxidative stress, cellular antioxidant
status also affects sensitivity to radiation. It has been shown that compared with the
radiation-sensitive mice, radiation-resistant mice have higher SOD and catalase enzyme
activities [22]. Antioxidant enzyme MnSOD upregulation is implicated in low dose
ionizing radiation (≤10 cGy) and fractionated ionizing radiation-induced adaptive
response, leading to radioresistance [18, 23]. Our previous study found that selective
inhibition of RelB-induced MnSOD after radiation treatment can sensitize prostate cancer
cells to radiation treatment [24]. Radiation also induces antioxidant enzyme
peroxiredoxin II [25, 26] expression and protects cancer cells from oxidative stressinduced damage.
In addition to the tumor cell genetic abnormality and intracellular stress response, the
microenvironment of a tumor, such as hypoxia, elevated growth factor expression, cell
adhesion molecule [27] and tumor angiogenesis [28], also contributes to the development
of radioresistance. Further understanding of the mechanisms of radioresistance in tumor
cells will help to improve the outcome of radiation therapy.

Oxidative stress
Oxidative stress refers to an imbalance between pro-oxidant and antioxidant that
favors the former, leading to potential damage. Both the increase in production of
reactive species (RS) and the decrease in antioxidants can lead to oxidative stress.
Reactive species, including ROS (reactive oxygen species) and RNS (reactive
nitrogen species), are free radicals that contain one or more unpaired electrons, such as
superoxide (O2·-), hydroxyl radical (OH·), nitric oxide (NO·), and non-radicals, such as
hydrogen peroxide (H2O2) and peroxynitrite (ONOO-). Reactive species can be produced
either endogenously or exogenously. The most important endogenous source of ROS is
the mitochondrial electron transport chain. Aerobic organisms use oxygen to facilitate the
energy production in the form of ATP, most often by mitochondrial oxidative
phosphorylation. During mitochondrial oxidative phosphorylation, electrons pass through
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the electron transport chain on the mitochondrial inner membrane and eventually reduce
the oxygen to water. However, some components of the mitochondrial electron transport
chain, such as complex I (NADH-dehydrogenase) and complex III (ubiquinonecytochrome b), can leak electrons directly to O2, leading to the one electron reduction of
O2 and generation of O2·-. It is estimated that 1-3% of the O2 reduced in mitochondria
may form O2·-. Superoxide can be dismutated by superoxide dismutase (SOD) to yield
hydrogen peroxide. In the presence of transition metal ions, in particular iron, hydrogen
peroxide is subsequently converted through Fenton and Haber-Weiss reactions to a
hydroxyl radical. Reactive species can also be generated by other enzymes, such as
xanthine oxidase (XO), membrane-associated NADPH oxidase and cytochrome P450 in
endoplasmic reticulum, oxidases in peroxisomes, NOS (nitric oxide synthase), and autooxidation of small molecules such as dopamine, epinephrine and flavins [29, 30]. The
exogenous sources of reactive species include irradiation (i.e., UV radiation, X-ray, ray), cigarette smoke and redox cycling of some chemicals, such as quinone and aromatic
nitro compound.
To counterbalance the production of reactive species, biological organisms develop
the antioxidant system (Figure 1.2). The enzymatic antioxidants include superoxide
dismutase (SOD), catalase, glutathione peroxidase (GPx), peroxiredoxin (Prx) and
glutathione S-transferase (GST). There are three forms of SODs in mammals:
cytoplasmic copper zinc SOD (SOD1), mitochondrial manganese superoxide dismutase
(SOD2) and extracellular copper zinc SOD (SOD3), which catalyze the dismutation of
superoxide into oxygen and hydrogen peroxide. Catalase, located in peroxisomes, is
responsible for the removal of hydrogen peroxide by direct decomposition of H2O2 to O2.
GPxs, localized in the cytosol, mitochondria and extracellular fluids, remove hydrogen
peroxide by coupling its reduction to H2O with oxidation of glutathione. Prxs, which are
widely distributed both intracellularly and extracellularly, also reduce hydrogen peroxide,
organic peroxides and peroxynitrite. The typical 2-cysteine Prxs are thioredoxindependent peroxide reductases. GST catalyzes the conjugation of glutathione with
electrophilic centers on a wide variety of substrates, including lipid hydroperoxide. GST
has also been reported to conjugate with 4-hydroxynonenal (4-HNE), the highly toxic
endproduct of lipid peoxidation. In addition to these antioxidant enzymes, small thiol-
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containing peptides, such as glutathione (GSH), glutaredoxin (Grx) and thioredoxin (Trx)
systems also help to scavenge reactive oxygen species and maintain other proteins in
their reduced state. The non-enzymatic antioxidants include, among others, Vitamin E,
Vitamin C, β-carotene and coenzyme Q.
It has been shown that the balance between prooxidant and antioxidant plays an
important role in cell survival and death. When the redox balance is shifted in favor of
prooxidants, oxidative damage to nucleic acids, lipids, and proteins can lead to changes in
cell function and cell viability. Depending on the cell type and the extent of the resulting
oxidative stress, the consequences of oxidative stress can be very different, from elevated
proliferation, induction of adaptive response, to cell injury, senescence and cell death. A
wide range of diseases and pathological conditions is associated with oxidative stress,
such as neurodegenerative diseases and cancer.

Oxidative stress and cancer
It has been postulated that oxidative stress is associated with tumor formation,
progression and metastasis. Reactive species can attack DNA, leading to various
oxidative DNA damages, such as 8-hydroxy-deoxyguanosine (8OH-dG). Nuclear
genomic DNA and mitochondrial DNA are both susceptible to oxidative damage.
Unrepaired DNA damage may result in mutations in oncogenes and tumor suppressor
genes, leading to carcinogenesis. Mutation and alteration of mitochondrial DNA also
contribute to the process of carcinogenesis. Reactive species can also act as signaling
molecules and regulate cell signaling pathways that are involved in cell growth and
apoptosis. For example, in response to oxidative stress, MAPK (mitogen activated protein
kinase) / AP-1 (activator protein-1) and NF-κB pathways are activated. The altered gene
expression downstream of these pathways leads to the stimulation of cell proliferation
and suppression of cell apoptosis, contributing to tumor progression [30]. Oxidative
stress may also promote tumor metastasis by altering the tumor microenvironment and
stimulating angiogenesis [31].
Prostate cancer cells have been shown to have increased level of oxidative stress
compared to normal prostate cells and the level of oxidative stress is proportional to the
aggressive phenotype [32]. The increased oxidative stress level in prostate cancer cells
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may result from an increase of ROS generation and/or a decrease in the antioxidants. The
increased ROS generation may come from mitochondria [33] or the NADPH oxidase
(NOX) system [32]. Prostate cancer has also been reported to have a lower antioxidant
defense system compared to normal prostate tissue. For example, lower antioxidant
enzymes MnSOD, CuZnSOD, catalase [34, 35], and defects in several classes of GSTs
[36], are observed in prostate cancer cells compared with benign prostate cells. The
antioxidant Nrf2 [Erythroid 2p45 (NF-E2)-related factor 2 (Nrf2)] pathway [37] is also
downregulated in prostate cancer cells.
Oxidative stress is not only involved in tumorigenesis, but also implicated in tumor
therapy. The small shift in cell redox status toward prooxidation will usually increase the
proliferation of tumor cells and be involved in tumorigenesis and tumor progression. A
highly oxidizing condition is strongly cytotoxic and is a primary mechanism for tumor
cell killing by radiation therapy and some chemotherapeutics, such as taxol and
adriamycin. Since tumor cells are under more oxidative stress than normal cells,
inhibition of antioxidant systems or exposure to further exogenous ROS insults would
cause more ROS-mediated damage in them. Therefore there is presumably a therapeutic
window for modifying cell redox status, which allows normal cells to maintain redox
homeostasis through adaptive response, but pushes the tumor cells, which are already
under high constitutive oxidative stress, beyond their tolerance, leading to selective
targeting of tumor cells in cancer therapy (Figure 1.3). A number of studies support this
hypothesis. Increasing cell H2O2 level by SOD mimics-mediated superoxide dismutation
has a differential effect on non-transformed NIH3T3 cells and CT26 colon and Hepa 1-6
liver tumor cells [38]. In NIH 3T3 cells, which have low levels of ROS, slightly elevated
H2O2 induces cell proliferation, but the same level of H2O2 leads to cell death in CT26
and Hepa 1-6 tumor cells, which have high levels of endogenous ROS. Regulating
intracellular redox state is also a good target to selectively sensitize cancer cells to
oxidative stress-inducing therapy, such as radiotherapy. For example, 2-Deoxy-D-glucose
(2-DG), a potent inhibitor of glucose metabolism, has been shown to preferentially
induce radiosensitization in transformed cells but not non-transformed cells via
perturbations in thiol metabolism [39]. Selenite sensitizes prostate cancer cells to
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radiation by altering the intracellular redox state and preferentially inducing apoptosis in
cancer cells [40].

Parthenolide
Parthenolide is a sesquiterpene lactone derived from the leaves of the traditional
herbal medicine feverfew (Tanacetum parthenium). Parthenolide has been traditionally
used in Europe to treat inflammatory diseases, such as fever, migraine, and arthritis [41].
More recently, it has been found to be a potent NF-κB inhibitor [42]. The biological
activity of parthenolide is thought to be mediated through the α-methylene-γ-lactone
moiety and the epoxide in its structure (Figure. 1.4). These functional groups can react
with nucleophiles, especially with cysteine thiol groups in a Michael addition reaction.
Recently, the anti-tumor property of parthenolide has attracted great interest among
researchers. Parthenolide has been shown to inhibit growth or induce apoptosis in a
number of tumor cell lines [43-47]. More remarkably, it has been shown that parthenolide
is cytotoxic to hepatoma cells and leukemia cells while sparing normal liver cells and
hematopoietic cells [43, 46], suggesting that the cytotoxic effect of parthenolide is
selective for tumor cells. Many mechanisms have been postulated as being involved in
the anti-tumor effect of parthenolide, including inhibition of nucleic acid synthesis [48,
49], depletion of thiols, induction of oxidative stress [43, 45, 46], induction of
mitochondria dysfunction [43], disruption of intracellular calcium equilibrium [45],
induction of cell cycle G2/M phase arrest [43, 44], depletion of HDAC1 (histone
deacetylase 1) [50], inhibition of tubulin carboxypeptidase activity [51], sustained
activation of JNK (c-Jun N-terminal kinase) [52, 53], inhibition of MAPK (mitogenactivated protein kinase) activity [54], activation of p53 [46, 55], suppression of STAT3
(signal transducer and activator of transcription 3) [56] and inhibition of NF-κB [46, 53]
activation. It has also been demonstrated that parthenolide sensitizes cancer cells to
various apoptosis-inducing agents mainly through inhibition of NF-κB [53, 57-60].
Inhibition of the NF-κB pathway by parthenolide is a well-established consequence of its
direct interaction with Cys residues in IKKβ and p65 [61-63].
Parthenolide has also been shown to play a dual role in regulating the intracellular
redox state. Direct reaction with the Cys thiols by parthenolide may lead to depletion of
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intracellular GSH and protein thiols and induction of ROS in some cancer cells [43, 45],
but another study suggests that parthenolide possibly increases GSH levels by activation
of the Nrf2-ARE (antioxidant/electrophile response element) pathway [64] in
hippocampal HT22 cells. Li-Weber et al. reported that parthenolide at low dose (up to 5
µmol/L) neutralizes H2O2 generated by the TCR (T cell receptor) signaling pathway in
Jurkat T cells and protects cells from CD3-induced apoptosis; at high dose (10 µmol/L),
it induces O2-·and generates oxidative stress, leading to an increase of dead cells [65].
Therefore, depending on the cell type and concentration, parthenolide may act as either a
prooxidant or an antioxidant under different conditions.
Since parthenolide not only inhibits NF-κB, which is known to be an important
mediator of radioresistance, but also regulates intracellular redox state, a determinative
factor for cell sensitivity to radiation, I hypothesize that parthenolide may sensitize
cancer cells to radiation treatment.

Thiol chemistry and biological importance
Thiols (-SH) are important in integrating intracellular redox changes with cellular
signaling transduction pathways. Thiols are easily oxidized and usually the oxidation
products can be reversibly reduced, making them a good candidate for signal transduction.
Thiols can react with almost every physiological oxidant, including superoxide, hydrogen
peroxide, nitric oxide and peroxynitrite. Different oxidants may induce different sets of
target thiol oxidation. The oxidation of thiols can form disulfide (-S-S-, including mixed
disulfides with glutathione or glutathionylation, -S-SG), sulfenic acid (-SOH), sulfinic
acid [-S(O)OH], sulfonic acid [-S(O)2OH], thiolsulfinate [-S(O)-S-], thiyl radical (-S·),
nitrosothiol (-SNO). Some of these oxidation products are not stable and are highly
reactive. For example, sulfenic acid or thiyl radical may further react to form disulfide.
The reactivities of thiol proteins and non-protein thiols are related to their structures,
hydrophobicity, pH, the availability of thiol group, abundance and competition for
oxidants, and also the pKa of the cysteine residue. Cysteine pKa values span a wide
spectrum from as high as 8.8 for cysteine in GSH, to 6.5 for thioredoxin and as low as 5.4
for the phosphatase PTP1 (protein tyrosine phosphatase 1). The reactivity of thiol protein
is generally inversely related to the pKa value. The lower the pKa is, the more reactive
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the thiol protein is. The cellular thiol redox state is controlled by two major systems, the
glutathione and thioredoxin. The glutathione/ glutathione reductase/ glutaredoxin (Grx)
system catalyzes the reduction of glutathionylated proteins, while thioredoxin/
thioredoxin reductase has greater specificity for protein disulfides. Both these systems
utilize NADPH as the ultimate source of electrons.
A number of regulatory proteins have cysteines on their active sites. The oxidation
and reduction of the cysteine thiols on these proteins have important effect on their
functions or act as the molecular switch for their downstream signaling cascades [66]. For
example, the cysteines on the active site of some kinases and phosphatases are sensitive
to reactive species induced oxidation. Phosphatases such as PTEN (phosphatase and
tensin homologue deleted from chromosome-10), PTP1B (protein tyrosine phosphatase
1B), and SHP-2 (Src homology 2 domain (SH2)-containing tyrosine phosphatase 2) have
been shown to form a sulfenic acid intermediate and to be inactivated by H2O2 mediated
oxidation. On the other hand, protein kinases and GTPases, such as Src tyrosine kinase
and Ras, are activated by cysteine oxidation. Many transcription factors also contain
redox sensitive cysteine residues. AP-1 (activator protein-1), Ref-1 (Redox factor-1), NFκB, and p53 all contain redox sensitive cysteine residue in their DNA binding domain.
The oxidation of these cysteine residues often leads to a decrease in DNA binding
activity. Proteins control activation and localization of transcription factors can be
oxidized as well, such as Keap1 (Kelch-like ECH-associated protein-1), which regulates
Nrf2, and IκB, which regulates NF-κB. Oxidation can also significantly change the
tertiary structure of proteins; thereby influencing their functional properties and
interactions with other proteins. For example, the oxidation of thioredoxin leads to its
dissociation from ASK-1 (apoptosis signal-regulating kinase 1), resulting in ASK-1
activation and induction of apoptosis.
Thiols could play a significant role in the resistance of tumor cells to
chemotherapeutic agents [67]. Modulation of thiol redox-related enzymes may be an
effective means of enhancing anticancer therapies. Depleting cellular thiols has been
shown to enhance radiation-induced cell death [68]. Parthenolide contains an αmethylene -lactone moiety, which is electrophilic and apt to react with biological
nucleophiles such as the thiol groups in proteins via a Michael addition reaction (Figure
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1.5). The chemical properties of parthenolide might make it a good candidate for
modifying cellular redox signaling and endow it with great potential in cancer therapy.

Research objectives
This study aims to address whether and how parthenolide can sensitize prostate
cancer cells to radiation treatment.
In chapter two, we report our investigation of whether parthenolide can sensitize
prostate cancer cells to radiation treatment by using different prostate cancer cell lines.
The studies were focused on investigating the role of NF-κB in the radiosensitization
effect of parthenolide. As we compared the effect of parthenolide in different prostate
cancer cell lines, we found that inhibition of NF-κB is a common but not exclusive
mechanism for the effect of parthenolide, which led us to study how parthenolide affects
the PI3K/Akt pathway and how PTEN influences cell sensitivity to parthenolide.
In chapter three, we report our comparison of the effect of parthenolide on prostate
cancer cells and normal prostate epithelial cells. Here, our study focused on how
parthenolide differentially regulates intracellular redox status and redox-related signaling
pathways in cancerous and noncancerous prostate cells.
The overall objective of this research is to investigate how parthenolide sensitizes
prostate cancer cells to radiation treatment and how the selective cancer killing effect is
achieved. The data also provide some experimental evidence for the potential clinical use
of parthenolide in cancer therapy.
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Figure 1.1 Possible reactions for the free radicals generated by radiation.

H2O → H2O+ + eH2O+ + H2O → H3O+ + OH·
OH·+ R-H → H2 + R·
e-aq + O2 → O2-·
e-aq, hydrated electrons, „aq‟ stands for aqueous.
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Figure 1.2 Scheme of cellular reactive species generation and antioxidant system.
Sources of reactive species: ETC, mitochondria electron transport chain; NOX, NADPH
oxidase; XO, xanthine oxidase; P450, cytochrome P450; NOS, nitric oxide synthase.
Antioxidant system: SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; GPx,
glutathione peroxidase; GR, glutathione reductase; TrxR, thioredoxin reductase; TRXox,
oxidized thioredoxin; TRXre, reduced thioredoxin; Prx, peroxiredoxin.
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Figure 1.3 The therapeutic window for selective targeting of tumor cells by
modulating cell redox status.
Under normal physiologic conditions, cell redox status is kept in balance. A small shift in
cell redox potential toward an oxidizing condition will activate repair or adaptive
signaling, leading to upregulation of the antioxidant system and increased oxidative
damage repair pathway, as well as promotion of cell proliferation. However, further shift
to an extreme oxidizing condition will activate the apoptotic or necrotic pathway, leading
to cell death. Tumor cells, compared to normal cells, are usually under oxidative stress
and have increased proliferation. Therefore, a further increase in oxidative stress will
easily disrupt the redox balance of tumor cells, leading to cell death. However, an
adaptive response enables normal cells to maintain redox balance. Therefore, a
therapeutic window which is determined by the redox difference between normal and
tumor cells exists for selective targeting of tumor cells by redox intervention.
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Figure 1.4 Chemical structure of parthenolide
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Figure 1.5 Parthenolide reacts with thiol group in a Michael addition reaction.
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Chapter Two
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by
NF-κB inhibition and enhanced by the presence of PTEN

Synopsis
Parthenolide has been shown to have anti-inflammatory and anti-tumor properties.
However, whether and how parthenolide enhances tumor sensitivity to radiation therapy
remain unknown. In this study, we demonstrate that inhibition of the NF-κB pathway is a
common mechanism for the radiosensitization effect of parthenolide in prostate cancer
cells LNCaP, DU145 and PC3. Parthenolide inhibits radiation-induced NF-κB DNA
binding activity and the expression of its downstream target Sod2, the gene coding for an
important anti-apoptotic and antioxidant enzyme (MnSOD) in the three prostate cancer
cell lines. Different susceptibilities to parthenolide‟s effect were observed in two
radioresistant cancer cells, DU145 and PC3, with DU145 cells showing higher sensitivity.
This differential susceptibility to parthenolide is due, in part, to the fact that in addition to
NF-κB inhibition, parthenolide activates the PI3K/Akt pro-survival pathway in both
DU145 and PC3 cell lines. However, the activated Akt in DU145 cells is kept at a
relatively low level compared to that in PC3 cells due to the presence of functional PTEN.
Transfection of wild-type PTEN into PTEN null cells, PC3, confers the enhanced
radiosensitization effect of parthenolide in PTEN-expressing cells. When PTEN
expression is knocked down in DU145 cells, the cells become more resistant to
parthenolide‟s effect. Taken together, these results suggest that parthenolide inhibits the
NF-κB pathway and activates the PI3K/Akt pathway in prostate cancer cells. The
radiosensitization effect of parthenolide is due, in part, to the inhibition of the NF-κB
pathway. The presence of PTEN enhances the radiosensitization effect of parthenolide, in
part, by suppressing the absolute amount of activated p-Akt.
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Introduction
Prostate cancer is the most common cancer type and the third leading cause of cancer
deaths of U.S. men in 2006 [69]. Radiation therapy is frequently used to treat early stage
and inoperable locally advanced prostate cancer. The outcome of radiation therapy can be
greatly improved if higher doses of radiation are applied, especially for patients with
unfavorable tumors (i.e., Stage T3 lesions, pretreatment PSA levels greater than 10 ng/ml,
or biopsy Gleason scores ≥7). For these patients, the 5-year cancer-free survival rate
increased from 41% to 75% when radiation dose was increased to more than 7200 cGy
[70]. However, the side effects and late complications resulting from high dose radiation
increase to an unacceptable level, which limits the use of high doses of radiation. Another
problem in radiation therapy is that tumor cells develop radioresistance. Therefore, it is
important to find agents that can effectively sensitize malignant tumor cells to radiation
therapy at low doses while minimizing radiation toxicity to surrounding organs.
Many mechanisms are involved in the development of radioresistance in tumor cells.
One possible mechanism is activation of the nuclear factor kappa B (NF-κB) signaling
pathway. It has been shown that about two-thirds of the biological damage caused by
radiation is due to free radical mediated indirect action [4]. NF-κB is a redox sensitive
transcription factor family that regulates cell survival and death. In response to radiationinduced reactive oxygen species (ROS), the NF-κB pathway is activated [71]. There are
five members in the NF-κB family: RelA (p65), RelB, c-Rel, NF-κB1 (p105/ p50) and
NF-κB2 (p100/ p52). NF-κB is normally sequestered in the cytoplasm by its inhibitor IκB
family members in an inactive complex. Two NF-κB activation pathways exist. The
classical pathway activates the IκB kinase complex (IKC), which consists of IKKα, IKKβ
and IKKγ, leading to IκBα phosphorylation, ubiquination and further degradation by the
26S proteasome. As a result, the p50:RelA dimer is released and translocated into the
nucleus. The alternative pathway activates the IKKα homodimer, leading to the partial
degradation of p100 and activation of the p52:RelB dimer. Russell and Tofilon reported
that radiation activates the classical NF-κB pathway by selective degradation of plasma
membrane-associated IκBα [72]. Our previous study shows that RelB is also activated by
radiation [24]. Activation of NF-κB induces transcription of its target genes, which are
involved in anti-apoptosis and tumor metastasis [73]. Among numerous NF-κB
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downstream targets, manganese superoxide dismutase (MnSOD) has been identified as a
constitutively and immediately accessible NF-κB target [74]. MnSOD is a nuclearencoded primary antioxidant enzyme localized in mitochondria. The known function of
MnSOD is to remove superoxide radicals in mitochondria [75]. Overexpression of
MnSOD is protective against radiation-induced cell death [24, 76-78].
We and others have demonstrated that NF-κB is constitutively activated in aggressive
prostate cancer [24, 79, 80], and may be responsible for the intrinsic radioresistance of
some prostate cancer cells. Thus, inhibition of the NF-κB pathway represents a target to
enhance the sensitivity of prostate cancer to radiation therapy.
Parthenolide is a major active component of the herbal medicine feverfew
(Tanacetum parthenium), which is conventionally used in Europe to treat inflammatory
diseases, such as fever, migraine, and arthritis [41]. Parthenolide has been shown to
inhibit growth or induce apoptosis in a number of tumor cell lines [43, 46, 47, 81]. More
remarkably, it has been shown that parthenolide is cytotoxic to hepatoma cells and
leukemia cells while sparing normal liver cells and hematopoietic cells [43, 46],
suggesting that the cytotoxic effect of parthenolide may be selective for tumor cells.
Many mechanisms are postulated as being involved in the anti-tumor effect of
parthenolide, including inhibition of nucleic acid synthesis [48], depletion of thiols,
induction of oxidative stress [43, 45], induction of mitochondria dysfunction [43],
disruption of intracellular calcium equilibrium [45], induction of cell cycle G2/M phase
arrest [43, 44], sustained activation of JNK [52, 53], and inhibition of NF-κB [53]. It has
also been demonstrated that parthenolide sensitizes cancer cells to various apoptosisinducing agents mainly through inhibition of NF-κB [57]. However, whether parthenolide
sensitizes cancer cells to radiation-induced cell death and whether inhibition of NF-κB is
sufficient for the radiosensitization effect of parthenolide remain unknown.
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumor
suppressor protein with dual-specificity protein phosphatase activity [82]. It
dephosphorylates focal adhesion kinase (FAK) [83, 84], a major regulator of the integrin
signalling pathway, as well as the Src-homology collagen protein (Shc), and thus inhibits
the growth factor-induced mitogen-activated protein (MAP) kinase signalling pathway
[85, 86]. PTEN also functions as a lipid phosphatase and dephosphorylates the second
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messenger

phosphatidylinositol-3,4,5-trisphosphate

(PIP3)

to

antagonize

the

phosphatidylinositol 3-kinase (PI3K) signalling pathway. Loss of chromosome 10q,
which harbors the PTEN gene, is found in about 60% of advanced prostate cancer [87].
Functional loss of PTEN and subsequent activation of the PI3K/Akt (v-akt murine
thymoma viral oncogene homologue 1, also called protein kinase B, PKB) pathway have
been widely implicated in prostate cancer progression to metastasis. In this study, we
used three prostate cancer cell lines, including the radiosensitive LNCaP cells and two
radioresistant cell lines, DU145 (PTEN wild-type) and PC3 (PTEN null), to investigate
whether PTEN cooperate with NF-κB in the radiosensitization effect of parthenolide.

Materials and Methods
Cell culture and treatment. Human prostate cancer cell lines LNCaP, DU145, and PC3
were obtained from American Type Culture Collection (Manassas, VA). LNCap and PC3
cells were cultured in RPMI medium 1640 (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum, 1% penicillin and streptomycin mixture, 1 mmol/L sodium
pyruvate, 10 mmol/L HEPES, 1% NEAA mixture (Cambrex), 1% MEM vitamin mixture
(Cellgro) and 2 mmol/L L-glutamine. DU145 cells were cultured in MEM medium
(Sigma) supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin
mixture, 1 mmol/L sodium pyruvate and 0.1 mmol/L non-essential amino acids. Cells
were grown in a 5% CO2 atmosphere at 37°C. Parthenolide stock solution (5 mmol/L)
was prepared in DMSO and diluted in culture medium to the indicated final concentration
for cell treatment. DMSO (0.1%) diluted in medium was used as vehicle control. A 130
kv X-ray machine (Faxitron X-ray Corporation) was used to radiate cells, with a dose rate
of 89.7 cGy/min.
Clonogenic survival assay. Cells were trypsinized and plated in triplicate into 6-well
plates at different densities based upon cell types and doses of radiation. LNCaP, DU145
and PC3 cells were plated at the density of 2,000-10,000 cells/well, 100-600 cells/well,
and 100-500 cells/well respectively. Cells were treated with indicated concentrations of
parthenolide or vehicle control for 24 hours prior to exposure to indicated doses of
radiation. Twenty-four hours after radiation treatment, the medium containing
parthenolide was removed and cells were maintained in normal culture medium. Twelve
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days after plating, cells were washed and stained with crystal violet, and the colonies
containing more than 50 cells were counted. Plating efficiency (PE) was calculated by
dividing the average number of cell colonies per well by the amount of cells plated.
Survival fractions were calculated by normalization to the plating efficiency of
appropriate control groups. The dose modifying factor (DMF) is calculated by the ratio of
the dose of radiation in the absence or presence of the drug to achieve the same cell
survival.
MTT assay. Cells were plated at the density of 5,000 cells/well into 96-well plates and
grew overnight. Then cells were pretreated with indicated concentrations of parthenolide
for 3 hours, and exposed to 6 Gy radiation or were sham-irradiated. Twenty-four hours
after radiation, parthenolide-containing medium was replaced with normal culturing
medium. Five days after radiation, 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT, 50 μg/well) was added and incubated at 37°C for 1 hour. After removal
of medium, DMSO 200 µL was added to each well to dissolve the purple formazan
crystal. The absorbance was measured at 540 nm. The cell survival was referenced to the
control group.
Nuclear extracts preparation and electrophoretic mobility shift assay (EMSA). Cells
were collected and suspended in 500 µL of buffer A (10 mmol/L HEPES-KOH with 1.5
mmol/L MgCl2, 10 mmol/L KCl, 0.2 mmol/L phenylmethylsulfonyl fluoride [PMSF],
500 µmol/L of DTT, and protease inhibitors). The samples were kept on ice for 15
minutes and vortexed vigorously for 15 seconds. The lysate was then centrifuged at
14,000 rpm for 30 seconds. The pellet was dissolved in 100 µL of buffer B (20 mmol/L
HEPES/KOH with 1.5 mmol/L MgCl2, 420 mmol/L NaCl, 25% glycerol, 0.2 mmol/L
PMSF, 500 µmol/L DTT, 0.2 mmol/L EDTA [pH 8.0], and protease inhibitors) and kept
on ice for 20 minutes followed by centrifugation at 12,000 rpm for 2 minutes. The
supernatant, identified as the nuclear extract, was frozen at –80°C. Protein concentration
was

determined

by

the

Bradford

method.

Double-stranded

oligonucleotides

corresponding to the consensus sequence of the NF-κB binding site (5'GAGACTGGGGAATACCCCAGT-3') were labeled with [32P]ATP. Reaction solution
(20 µL) containing 5 µg of the nuclear extract, 4 µL of 5× binding buffer (50 mmol/L
Tris-HCl [pH 7.5], with 20% glycerol, 5 mmol/L MgCl2, 2.5 mmol/L EDTA, 5 mmol/L
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DTT, and 0.25 mg/mL poly dI-dC) and 1 µL [32P]-labeled probe, was incubated at room
temperature for 20 minutes. Samples were separated on 4% polyacrylamide gel and
visualized by phosphorimaging.
Western blot analysis. For each treatment group, a certain amount of the whole cell
lysate was separated on 10% SDS-PAGE gel and transferred onto nitrocellulose
membrane. After blocking in 5% milk for 1 hour, the membrane was incubated with the
primary antibody and then the corresponding secondary antibody. The signals were
detected by enhanced ECL system and quantified by Quantity One® (Bio-Rad). AntiMnSOD antibody was purchased from Upstate, anti-actin antibody from Sigma, Akt and
phosphor-Akt (Ser473) antibody from Cell Signaling Technology, PTEN antibody from
Santa Cruz Biotechnology.
SOD activity gel electrophoresis. Cellular SOD activities were measured based on the
inhibition of the reduction of nitroblue tetrazolium (NBT) by SOD as described by
Beauchamp and Fridovich [88]. Briefly, 50 µg protein samples in 0.05 mol/L phosphate
buffer were loaded on 12.5% native polyacrylamide gel. Electrophoresis was conducted
overnight at 4 °C. Following electrophoresis, the gel was stained in the dark for SOD
activity with 2.43 mmol/L NBT for 20 minutes, riboflavin-TEMED solution for 15
minutes, and then exposed to light. The achromatic bands demonstrated the presence of
SOD activity.
Transfection of cells with plasmid DNA and siRNA and determination of cell
survival by trypan blue exclusion assay. The green fluorescent protein (GFP)-PTEN
expression construct was kindly provided by Dr. Vivek M. Rangnekar (University of
Kentucky). PTEN siRNA and scrambled control siRNA were purchased from Santa Cruz
Biotechnology. Cells were plated into 12-well plates, and transiently transfected with
GFP-PTEN expression plasmid and GFP control plasmid, PTEN siRNA and control
siRNA by using LipofectamineTM 2000 (Invitrogen, CA) according to the manufacturer's
instructions. Briefly, 1 µg plasmid DNA or 36 pmol siRNA was mixed with 50 µL
incomplete medium without fetal bovine serum and antibiotics and then complexed with
a mixture of 3 µL of Lipofectamine and 50 µL of incomplete medium for 20 minutes at
room temperature. The mixture was diluted with 500 µL of incomplete medium and
added to the cells. After 5 hours, the medium was replaced with 1ml of complete medium
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containing 10% fetal bovine serum and incubated overnight. Parthenolide was added to
the medium, and 24 hours later, cells were treated with 6 Gy radiation or were shamirradiated. After another 24 hours, the cells were processed for trypan blue exclusion
assay and collected for Western blot analysis. Cell suspension (20 µL) was mixed with 20
µL 0.04% trypan blue solution and loaded on to a hemocytometer. Cells were counted
under a light microscope. Dead cells retained the dye while the viable cells excluded
trypan blue and appeared bright. Cell survival was calculated against the relative control
group.
Statistical analysis. Statistical analysis was done by using either Student's t test (for twogroup comparison) or one-way ANOVA (for multiple-group comparison). Data are
reported as mean ±SD.

Results
Parthenolide’s efficiency in sensitizing LNCaP, DU145 and PC3 cells to radiation
treatment differs.
To determine whether parthenolide can enhance the sensitivity of prostate cancer
cells to radiation treatment, three human prostate cancer cell lines LNCaP, DU145 and
PC3, were plated for clonogenic cell survival assay. In the absence of parthenolide,
LNCaP cells were much more sensitive to radiation treatment than DU145 and PC3 cells
were (Figure 2.1 A), which is consistent with our previous result [24]. Radiation, 2 Gy,
killed 46% of LNCaP cells but only approximately 10-25% of DU145 and PC3 cells.
Parthenolide sensitized all three prostate cancer cell lines to radiation treatment in a dosedependent manner. LNCaP cells were most sensitive to parthenolide treatment. The
lowest concentration of parthenolide to show a radiosensitization effect at 2 Gy radiation
was 0.25 µmol/L in LNCaP cells; 0.5 µmol/L in DU145 cells and 1.5 µmol/L in PC3
cells. Since LNCaP cells showed high sensitivity to radiation alone, we focused our study
of the radiosensitization effect of parthenolide on the radioresistant aggressive prostate
cancer cell lines DU145 and PC3. In these two cell lines, DU145 showed significantly
greater sensitivity to parthenolide treatment. The DMF of 1.0 µmol/L parthenolide at 0.37
survival fraction (D1) was 1.8 in DU145 cells and 1.3 in PC3 cells. For 1.5 µmol/L
parthenolide, the DMF was 2.6 in DU145 cells and 1.6 in PC3 cells. The different
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radiosensitization efficiency of parthenolide in DU145 and PC3 cells was further
demonstrated by the MTT assay (Figure 2.1 B). Due to a higher cell density used in MTT
assays compared to clonogenic assays, higher concentrations of parthenolide were used.
Consistent with the results of clonogenic survival assay, the radiosensitization effect of
parthenolide was dose-dependent in both DU145 and PC3 cells (Figure 2.1 B), with 5
µmol/L parthenolide showing the most dramatic effect. There was no significant
difference between the radiosensitivity of DU145 cells and PC3 cells in the absence of
parthenolide. The relative cell survival after 6 Gy radiation was 0.62±0.03 in DU145 cells,
and 0.68±0.03 in PC3 cells (p>0.05) in the absence of parthenolide. Parthenolide showed
higher toxicity and higher radiosensitization effect in DU145 cells than in PC3 cells. On
the fifth day after 5 µmol/L parthenolide treatment, the relative cell survival fraction was
only 0.12 in DU145 cells, whereas it was 0.65 in PC3 cells. After 6 Gy radiation, the
relative cell survival decreased from 0.12 to 0.02 (decrease of 83.3%) in the presence of 5
µmol/L parthenolide in DU145 cells, while in PC3 cells it decreased from 0.65 to 0.21
(decrease of 67.8%). Due to the high cell density for determing biochemical and
molecular biology endpoints, we used 5 µmol/L parthenolide in all subsequent studies.

Parthenolide inhibits radiation-induced NF-κB activation in prostate cancer cells.
Nuclear extracts from cells treated with radiation in the absence or presence of
parthenolide were analyzed for NF-κB DNA-binding activity by EMSA. NF-κB DNA
binding activity was clearly increased by 6 hours after radiation in all three cell lines
(Figure 2.2 A). DU145 and PC3 showed higher NF-κB DNA-binding activity compared
to LNCaP cells (Figure 2.2 B), which is consistent with the aggressive and radioresistant
characteristics of these two cell lines. Parthenolide inhibited radiation-induced NF-κB
DNA binding activity in all three cancer cell lines, especially the p65/p50 hetero-dimer
binding activity, which is shown as the top band on the gel since it can be super-shifted
by both p65 and p50 antibodies (Figure 2.2 B). This result is consistent with previous
reports that parthenolide can inhibit NF-κB activity by direct targeting at IκB Kinase
Complex (IKC) [61, 89], thus inhibiting NF-κB nuclear translocation and targeting p65
[62, 63] and directly inhibiting its DNA binding activity. Since NF-κB activation has
been well established as a mediator of radioresistance [90], these results suggest that
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parthenolide may exert its radiosensitization effect in prostate cancer cells by inhibiting
radiation-induced NF-κB activation, thereby suppressing the transcription of NF-κB
target genes involved in regulating cell survival and death.

Parthenolide suppresses MnSOD induction by radiation in prostate cancer cells.
Radiation exerts its effect largely by inducing oxidative stress. MnSOD is an
important antioxidant enzyme induced by radiation. Therefore, we determined the effect
of parthenolide on the expression of MnSOD, a well-established radiation-induced NF-κB
target gene [24, 91]. Radiation induced MnSOD protein levels of all three prostate cancer
cell lines at 24 and 48 hours after radiation (Figure 2.3 A). In DU145 and PC3 cells, the
induction of MnSOD was higher than in LNCaP cells (Figure 2.3 B), which is consistent
with the relative radioresistance of these two cell lines. Parthenolide suppressed
radiation-induced MnSOD in all three cancer cell lines used. This further demonstrated
that the transcription activity of NF-κB was inhibited in all three cancer cell lines.
Consistent with the changes in MnSOD protein levels, the increase in MnSOD activity by
radiation, determined by SOD activity gel electrophoresis, was also suppressed in the
presence of parthenolide in PC3 cells (Figure 2.3 C). CuZnSOD activity was used as a
loading control which did not change significantly with treatment. Suppression of
MnSOD will expose cells to radiation-induced oxidative stress; thus, this result suggests
that the radiosensitization effect of parthenolide may be partially mediated through
inhibition of radiation-induced MnSOD expression.

Parthenolide activates Akt.
A greater radiosensitization effect of parthenolide was observed in DU145 cells than
in PC3 cells (Figure 2.1). Both DU145 cells and PC3 cells are androgen-independent
radioresistant aggressive prostate cancer. Neither has any functional p53 and they are
known to have comparable levels of NF-κB [92]. One of the major differences of these
two cell lines is their PTEN status. DU145 cell is known to have functional PTEN,
whereas PC3 cell is PTEN null. The major function of PTEN is to dephosphorylate the
second messenger PIP3 and to antagonize the PI3K/Akt, a pro-survival pathway. To
elucidate the effects of PTEN on the differential radiosensitization efficiency of
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parthenolide in these two prostate cancer cell lines, we determined the effect of
parthenolide on Akt activation. When we loaded 30 µg of proteins from both PC3 and
DU145 whole cell lysates, as expected, PTEN-competent DU145 cells expressed a much
lower level of activated p-Akt compared with PC3 cells at baseline (Figure 2.4 A).
However, in order to ensure the detection of p-Akt in DU145 cells, protein was
overloaded in PC3 cells, and therefore the changes in p-Akt level caused by radiation and
parthenolide were not in the linear range for densitometry. To demonstrate a better trend
of treatment-induced changes in the p-Akt levels in these two cell lines, we loaded
different amounts of protein for the two cell lines so that the levels of p-Akt were in the
linear range. Radiation induced the phosphorylation of Akt in both cell lines, with the
induction peaking at 1 hour after radiation (Figure 2.4 B). A previous study showed that
activation of Akt after radiation is very rapid (10~15 min) [93], and our data confirm that
this is an early event. The differences in peak times appear to be cell-type specific.
Parthenolide alone increased the phosphorylation of Akt. When radiation was combined
with parthenolide, greater induction of Akt phosphorylation was observed in both cell
lines. In DU145 cells, which have wild type PTEN, the phosphorylation of Akt was kept
at a relatively low level compared to that in PC3 cells. Even with combined radiation and
parthenolide treatments, the level of p-Akt in DU145 cells remianed lower than the basal
level in PC3 cells (Figure 2.4 A). Consistent with the pro-survival role of the p-Akt
pathway, the radiosensitization effect of parthenolide was lower in PC3 cells, which have
much higher levels of p-Akt after parthenolide treatment compared to DU145 cells
similarly treated.

PTEN enhances the radiosensitization effect of parthenolide.
To directly test the role of PTEN in the radiosensitization effect of parthenolide in the
two prostate cancer cell lines, we overexpressed PTEN in the PTEN null cell line PC3
and knocked down PTEN expression in PTEN-expressing cell line DU145 and
determined cell survival after radiation and parthenolide treatment. We transfected GFP
control plasmid and GFP-PTEN expression plasmid into PC3 cells. The transfection
efficiency was approximately 85% based upon the percentage of GFP positive cells under
fluorescent microscope (data not shown). Compared to the cells transfected with GFP
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control, in the presence of GFP-PTEN expression, the normalized cell survival level was
decreased by 44% when treated with 5 µmol/L parthenolide alone, 16% when treated
with 6 Gy radiation alone and 68% when treated with parthenolide combined with
radiation (Figure 2.5 A). Overexpression of GFP-PTEN in PC3 cells conferred the cells
more susceptible to parthenolide and radiation toxicity, and also enhanced the
radiosensitization effect of parthenolide. Consistent with the role of PTEN, the
phosphorylation of Akt induced by parthenolide, radiation and combined treatment was
inhibited in the presence of GFP-PTEN (Figure 2.5 A). In a complementary experiment,
PTEN was knocked down in DU145 cells by using PTEN siRNA. Compared to the cells
transfected with control siRNA, the normalized cell survival when PTEN expression was
knocked down, was increased by 53% when treated with 5 µmol/L parthenolide alone, 54%
when treated with 6 Gy radiation alone, and 74% when treated with parthenolide
combined with radiation (Figure 2.5 B). Abrogation of PTEN expression in DU145 cells
rendered the cells more resistant to the combined effect of parthenolide and radiation.
Consistently, the phosphorylation of Akt induced by parthenolide, radiation and
combined treatment was further increased when PTEN expression was knocked down
(Figure 2.5 B). Together, these results suggest that the presence of PTEN enhances the
radiosensitization effect of parthenolide.

Discussion
Our results demonstrate that parthenolide sensitizes prostate cancer cells to radiation
treatment. Among the three prostate cancer cell lines used in our study, LNCaP cells
express androgen receptor (AR) and have wild-type p53. Both DU145 and PC3 cells are
AR negative and have no functional p53 [94]. The androgen responsive LNCaP cells
showed higher sensitivity to radiation treatment, which is consistent with previous studies
[24, 95]. Several factors can contribute to the fact that LNCaP cells are sensitive to
radiation: 1) LNCaP cells have functional p53; 2) The activity of NF-κB in LNCaP cells
is low, and RelB level is especially low [24]. 3) The presence of AR in LNCaP cells is
antagonistic to NF-κB function [96, 97]. Since LNCaP cells are sensitive to radiation
treatment, our studies of the radiosensitization effect of parthenolide have been focused
on the radioresistant cell lines, DU145 and PC3.
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It has been shown that parthenolide inhibits the NF-κB pathway by targeting IKC [61,
89] or directly modifying p65 [62]. The α-methylene-γ-lactone functional group in
parthenolide can react with nucleophiles, such as cysteine sulfhydryl groups, in a Michael
addition reaction [98]. Inhibition of the NF-κB pathway by parthenolide is considered to
be a consequence of alkylation of cysteine 179 of IKKβ or cysteine 38 of p65. Previous
studies have shown that parthenolide sensitizes cancer cells to various apoptosis-inducing
agents through inhibition of NF-κB [57]. In our study, inhibition of NF-κB and its
downstream target, MnSOD, appears to be a common mechanism for the
radiosensitization effect of parthenolide in the prostate cancer cell lines studied. NF-κB
activation induces many genes with anti-apoptotic activities, including MnSOD, a
mitochondria antioxidant enzyme that scavenges ROS. Inhibition of the NF-κB pathway
has been shown to sensitize prostate cancer cells to radiation treatment. Kim et al [21]
demonstrated that using proteosome inhibitor-1 to inhibit NF-κB activation can increase
the radiosensitivity of Ki-Ras transformed human prostate epithelial 267B1/K-ras cells.
Our previous finding demonstrated that selective inhibition of RelB by dominant negative
p100 significantly sensitizes prostate cancer cells to ionizing radiation [24]. The present
study extends those findings to demonstrate that parthenolide inhibits radiation-induced
NF-κB activation in all prostate cancer cell lines tested (Figure 2.2 A) and sensitizes them
to radiation treatment.
MnSOD is a key antioxidant enzyme that regulates cell transformation, tumor growth,
and cell response to stress-inducing therapeutic regimens [99]. Previous studies have
shown that radiation induces cellular ROS levels and MnSOD expression. Inhibition of
MnSOD expression by antisense MnSOD or selective inhibition of RelB can enhance the
radiosensitivity of tumor cells [23, 24]. In the present study, we show that parthenolide
inhibits radiation-induced MnSOD expression in three prostate cancer cell lines (Figure
2.3). Since MnSOD is capable of removing superoxides generated by radiation, the
radiosensitization effect of parthenolide is likely to be mediated, in part, by the inhibition
of MnSOD expression and activity.
Although our results show that parthenolide sensitizes both radioresistant prostate
cancer cells, DU145 and PC3, to radiation in a dose-dependent manner (Figure 2.1 A),
the efficiencies of parthenolide‟s effect are different in the two cell lines. Higher toxicity

28

and a higher radiosensitization effect of parthenolide were observed in DU145 cells.
Similar activities (Figure 2.2 B) and levels [92] of NF-κB, and a similar level of
inhibition of the NF-κB target gene, MnSOD, by parthenolide (Figure 3.3 B) were
detected in the two radioresistant prostate cancer cell lines. Therefore, the difference in
the susceptibility of the two cell lines to parthenolide suggests that, in addition to
inhibition of NF-κB, other mechanisms may be involved in the effect of parthenolide. We
tested this hypothesis by examining the effect of parthenolide on the PI3K/Akt pathway
in the two cell lines with different PTEN status. Our results suggest that the PI3K/Akt
pathway is activated by parthenolide and the different cellular status of PTEN makes a
difference in cell susceptibility to parthenolide‟s effect. The PI3K/Akt pathway is
activated in response to growth factors and adhesion to matrix or other cells. It promotes
normal cell growth and proliferation. Activated PI3K converts PI(4,5)P2 to PI(3,4,5)P3
(PIP3), which is a lipid second messenger that activates many downstream molecules by
binding to their pleckstrin-homology (PH) domains. PIP3 recruits Akt to the cell
membrane and allows phosphatidylinositol-dependent kinase 1 (PDK1) and a second
kinase (termed PDK2, though not yet conclusively identified) to phosphorylate and
activate Akt at thr308 and ser473, respectively. Activated Akt promotes both cell growth
and cell survival by phosphorylation and inactivation of its downstream substrates
including glycogen synthase kinase 3 (GSK3), the proapoptotic protein BCL2-antagonist
of cell death (BAD), and the forkhead (FOXO) family of transcription factors, which
promotes expression of p27-Kip1, a cell-cycle inhibitor. It also activates the mammalian
target of rapamycin (mTOR) by phosphorylating and inactivating tuberous sclerosis
complex 2 (TSC2), thus promoting protein synthesis. The pro-survival role of Akt
accounts for its transforming potential and for the resistance of cancer cells to some
chemotherapeutic agents and ionizing radiation [100, 101]. Radiation-induced activation
of the PI3K/Akt pro-survival pathway is considered to be an important contributor to
radioresistance in cancer cells. Gottschalk et al [102] demonstrated that PI3K inhibitor
LY294002 sensitized prostate cancer cells to radiation through inactivation of Akt. Cao et
al. [103] showed that the mTOR inhibitor RAD001 sensitized prostate cancer cells to
radiation treatment. Our results demonstrate (Figure 2.4 B) that the PI3K/Akt pathway is
activated by radiation in two radioresistant prostate cancer cell lines. This may contribute
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to their radioresistance. When parthenolide activates the PI3K/Akt pathway, its
radiosensitization effect resulting from inhibition of the NF-κB pathway may be
counteracted. Thus, the activation of the PI3K/Akt pathway by parthenolide participates
in determining cell susceptibility to its radiosensitization effect.

Significant

radiosensitization effect was observed in the two radioresistant prostate cancer cell lines
in spite of the activation of the PI3K/Akt pathway, and this fact suggests that
parthenolide‟s inhibition of the NF-κB pathway overwhelms its effect of activating the
PI3K/Akt pathway in determining cell response to radiation.
PTEN is a tumor suppressor which antagonizes PI3K by degrading PI(3,4,5)P3 back
to PI(4,5)P2. PTEN mutations have been identified in 10-15% of all prostate cancers [104]
and in up to 60% of advanced prostate cancers with multiple metastases or in prostate
cancer cell lines [105]. Haploinsufficiency of the PTEN gene has been shown to promote
prostate cancer progression in a transgenic mouse model [106]. The PI3K/Akt pathway
can be activated by the deletion of PTEN [102]. Loss of functional PTEN and the
subsequent activation of the PI3K/Akt pathway may render cells more resistant to
radiation treatment in advanced prostate cancer. Rosser et al. [107] showed that
adenoviral-mediated PTEN transgene expression sensitizes prostate cancer cells to
radiation. Our results confirm the result from the earlier study and extend to demonstrate
that the presence of PTEN enhances the radiosensitization effect of parthenolide, in part,
by suppressing the absolute amount of activated p-Akt. Our data suggest that the
radiosensitization effect of parthenolide will be less effective in aggressive prostate
cancer cells lacking wild-type PTEN.
In summary, the present study demonstrates that parthenolide exerts its
radiosensitization effect in prostate cancer cells, in part, by inhibiting the NF-κB pathway
and its downstream target MnSOD. However, parthenolide also activates the PI3K/Akt
pro-survival pathway, which might also affect a cell‟s susceptibility to parthenolide. The
presence of PTEN enhances the radiosensitization effect of parthenolide by antagonizing
the PI3K/Akt pathway. Understanding the mechanisms that are involved in the
radiosensitization effect of parthenolide will enhance our ability to further improve the
use of parthenolide as an effective adjuvant in radiation therapy of prostate cancer.
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Figure 2.1 Parthenolide sensitizes prostate cancer cells to radiation treatment.
A. Clonogenic survival assay. Cells were treated with the indicated concentrations of
parthenolide (PN) for 24 hours, and then exposed to indicated doses of radiation. Twentyfour hours after radiation, the media containing PN was removed. Cells were then
maintained for 9 days. The cultures were stained and the colonies containing more than
50 cells were counted. Survival fraction was determined by dividing the plating
efficiency of radiated cultures by the plating efficiency of non-radiated cultures. Values
shown are the means ± SD for triplicates. * p<0.05 compared with DMSO treated
counterpart.
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B. MTT assay. Cells were pretreated with the indicated concentrations of parthenolide for
3 hours, and then exposed to 6 Gy radiation. Twenty-four hours after radiation, the media
containing PN was removed. Cells were then maintained for 4 days.
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Figure 2.2 Parthenolide inhibits radiation induced NF-κB DNA binding activity in
prostate cancer cells.
A. Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before ionizing
radiation (IR). Nuclear extracts (NE) were prepared at 6 hours after 6 Gy IR for
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Figure 2.3 Parthenolide suppresses MnSOD induction by radiation in prostate
cancer cells.
Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation.
Whole cell lysates were prepared at indicated times after 6 Gy radiation for detection of
MnSOD protein levels and activities.
A. Representative Western blots.
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B. Quantitation of MnSOD protein levels from 3 independent experiments. *p<0.05
Compared with radiation untreated control; # p<0.05 Compared with DMSO treated
counterpart.
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C. Representative SOD activity gels of PC3 cells from 4 independent experiments.
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Figure 2.4 Parthenolide activates Akt in PC3 and DU145 cells.
Cells were pretreated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation.
Whole cell lysates were prepared at indicated times after 6 Gy radiation. The fold
changes of p-Akt/Total Akt were normalized to no treatment controls.
A. Protein samples (30 µg) from both cell lines were loaded on the same gel to compare
the relative protein level of these two cell lines.
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B. Protein samples from PC3 cells (15 µg) and from DU145 cells (50 µg) were loaded
separately to demonstrate changes in protein levels after treatments.
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Figure 2.5 The presence of PTEN enhances the radiosensitization effect of
parthenolide.
A. PC3 cells were transiently transfected with GFP control plasmid and GFP-PTEN

expression plasmid. Parthenolide was added to the medium, and 24 hours later, cells were
treated with 6 Gy radiation or were sham-irradiated. After an additional 24 hours, the
cells were processed for trypan blue exclusion assay and collected for Western blotting.
Cytotoxicity was normalized to the corresponding control group. * p<0.05 compared with
the cells transfected with GFP control plasmid. The fold changes of p-Akt/Total Akt were
normalized to no treatment control.
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B. DU145 cells were transiently transfected with control siRNA and PTEN siRNA. Cells
were treated in the same way indicated in A for cytotoxicity assay and Western blot. *
p<0.05 compared with the cells transfected with control siRNA.
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Figure 2.6 Summary of chapter two
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Chapter Three
A NADPH oxidase dependent redox signaling pathway mediates the selective
radiosensitization effect of parthenolide in prostate cancer cells

Synopsis
We previously reported that parthenolide enhances the radiation sensitivity of prostate
cancer cells, in part, by inhibiting the NF-κB pathway. However, we have also found that
parthenolide activates the PI3K/Akt pathway. Using survival indexes determined by
MTT and growth rate assays, we found that parthenolide selectively exhibits a
radiosensitization effect on prostate cancer PC3 cells but not normal prostate epithelial
PrEC cells. Parthenolide selectively induces oxidative stress in PC3 cells but not in PrEC
cells, as determined by the oxidation of ROS sensitive probe H2DCFDA and the
intracellular reduced thiol and disulfide levels. Importantly, when combined with
radiation, parthenolide further increases ROS levels in PC3 cells, while it slightly
decreases radiation-induced oxidative stress in PrEC cells. Parthenolide activates
NADPH oxidase, an important source of ROS, in PC3 cells but not in PrEC cells. The
reduced thioredoxin, an important antioxidant, is significantly decreased after
parthenolide treatment in PC3 cells as a downstream event of NADPH oxidase activation.
The activation of NADPH oxidase also leads to the PI3K/Akt activation and consequent
FOXO3a phosphorylation. The NADPH oxidase dependent phosphorylation of FOXO3a
leads to the down-regulation of its targets, antioxidant enzyme MnSOD and catalase, in
PC3 cells. Together, our data suggest that NADPH oxidase mediates intense oxidative
stress by both increasing ROS generation and decreasing antioxidant defense capacity.
This results in a dramatic enhancement of oxidative stress and the selective
radiosensitization effect of parthenolide in prostate cancer cells.
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Introduction
Selective cancer killing without harming normal tissues is a fundamental challenge in
cancer therapy. Cancer cells are usually under increased oxidative stress compared with
normal cells. For example, prostate cancer cells often have increased ROS generation
from mitochondria [33] or the NADPH oxidase (NOX) system [32], and decreased
antioxidant enzymes, such as MnSOD, CuZnSOD and catalase [34, 35]. In response to
increased oxidative stress, cells may show elevated proliferation, induction of adaptive
response, cell injury, or even cell death depending on the intensity of the stress. It is
hypothesized that exposure to further exogenous ROS would push the tumor cells, which
already have high constitutive oxidative stress levels to cell death, while normal cells
may still maintain redox homeostasis through adaptive responses. Therefore, regulating
intracellular redox state represents an ideal target to selectively sensitize cancer cells to
oxidative stress-inducing therapy, such as radiotherapy. Radiation has been used
extensively to treat prostate cancer, either alone or in combination with other types of
cancer treatment. About 70% of the biological damage caused by radiation is due to the
generation of ROS [4]. Oxidative stress has also been shown to be a major mechanism for
parthenolide [43] induced cell death. Our previous study showed that parthenolide
sensitizes human prostate cancer cells to radiation treatment through inhibiting the NFκB pathway [108]. However, whether the radiosensitization effect of parthenolide is
selective to prostate cancer cells but not normal prostate cells, and whether parthenolide
regulates intracellular redox state differentially in cancer and normal cells, are unknown.
NADPH oxidase is an important source of ROS. It accounts at least partially for the
increased levels of ROS in prostate cancer [32, 109]. The first discovered NADPH
oxidase is phagocyte NADPH oxidase. It is a multisubunit enzyme localized to cell
membranes, consisting of membrane-bound components (gp91phox and p22phox) and
cytosolic components (p47phox, p67phox, p40phox and Rac) that translocate to the membrane
upon activation. Homologues of gp91phox (Nox2), including Nox1-5, Duox1 (dual
oxidase) and Duox2, have been identified and named as Nox (NADPH oxidase) proteins
in non-phagocytic cells. Their activation requires p47phox paralog Noxo1 (Nox organizer
1) and p67phox paralog Noxa1 (Nox activator 1), or calcium binding [110]. In general,
Nox proteins have binding sites for NADPH, FAD (flavin adenine dinucleotide) and
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hemes, and catalyze the transfer of an electron to molecular oxygen to generate
superoxide anion (O2·-), which is then enzymatically dismutated to H2O2. Eighty percent
of human prostate tumor samples show markedly increased Nox1 protein and mRNA
levels [109]. NADPH oxidase-mediated generation of ROS has been shown to be an
important contributor to X-ray induced cell death [8, 111]. However, whether
parthenolide activates NADPH oxidase in prostate cancer cells is unknown.
Glutathione (GSH) and thioredoxin (Trx) are important intracellular thiol-containing
antioxidants. Disrupting GSH and Trx systems will impair cellular antioxidant activity
and exacerbate radiation-induced oxidative stress. Parthenolide is a sesquiterpene lactone,
which can react with cysteine thiol groups via a Michael addition reaction. It has been
reported that parthenolide can deplete intracellular GSH and induce oxidative stress in
hepatoma cells [43]. However, the effect of parthenolide on Trx has not been elucidated.
In the previous study, we found that parthenolide activates the phosphatidylinositol 3kinase (PI3K)/Akt pathway in prostate cancer cells and that the cellular p-Akt level might
affect cell sensitivity to parthenolide [108]. Activated Akt is known to inhibit apoptosis
and promote cell survival by activation of the mammalian target of rapamycin (mTOR)
or direct phosphorylation and inactivation of its downstream targets, including glycogen
synthase kinase 3 (GSK3), the proapoptotic protein BCL2-antagonist of cell death (BAD),
and Forkhead box class O (FOXO) transcription factors. In contrast to the well-known
pro-survival role of Akt, some recent studies suggest that the PI3K/Akt pathway may
induce oxidative stress and trigger cell death under certain conditions [112]. The
mechanisms by which Akt induces ROS may involve: 1) stimulation of mitochondrial
oxidative metabolism; 2) reduction of antioxidant defense via FOXO suppression.
The FOXO transcription factors are mammalian homologues of DAF-16, which
regulates longevity in Caenorhabditis elegans. There are four members of the FOXO
family: FOXO1 (FKHR), FOXO3a (FKHRL1), FOXO4 (AFX) and FOXO6. Among
them, FOXO1 and FOXO3a are the most highly expressed FOXO proteins in human
prostate [101]. FOXO factors perform diverse functions by regulating the transcription of
their downstream targets which are involved in a variety of cellular processes, including
cell cycle and cell death regulation, differentiation and development, cellular stress
response, and energy metabolism control [113, 114]. In prostate cancer, FOXOs have
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been shown to inhibit tumorigenesis. FOXO1 deletion is detected in more than 30% of
prostate cancer specimens [115]; FOXO3a hyper-phosphorylation and inactivation has
been associated with the progression of prostate cancer to androgen independence [116].
Overexpression of FOXO1 and FOXO3a in the prostate cancer cell line provokes
apoptosis [117]. However, FOXOs also extend mammalian lifespan by protecting cells
against oxidative stress-induced cell death [118]. As the cellular functions of
FOXOs are diverse and in some cases appear to be antagonistic, it is postulated that the
activity of FOXO transcription factors is differentially regulated in specific tissues in
response to various types or intensities of external stimuli [119]. The regulation of
FOXOs is mostly achieved by changes in posttranslational modifications on the FOXO
proteins, including phosphorylation, acetylation, mono- and poly-ubiquitination. External
stimuli may regulate FOXO subcellular localization through phosphorylation. The
phosphorylation of FOXO by Akt is inhibitory phosphorylation, which allows the
chaperone protein 14-3-3 to bind to FOXO factors in the nucleus, enhances FOXO
nuclear export and decreases FOXO nuclear reentry, leading to cytoplasmic sequestration.
On the contrary, the phosphorylation of FOXO by oxidative stress-activated MST1
(mammalian Ste20-like kinase) and JNK (c-jun terminal kinase) pathways disrupts 14-33 binding and triggers the relocalization of FOXO from the cytoplasm to the nucleus, and
therefore it can be regarded as an activation phosphorylation. Radiation induces FOXO3a
nuclear translocation and activates FOXO3a activity [120, 121]. Activation of FOXO3a
by radiation may induce cell apoptosis by upregulating its targets, FasL and Bim [120];
but on the other hand, it also inhibits cell cycle progression and protects cells against
oxidative damage and genotoxic stress [118, 121-123] by upregulating cell cycle
inhibitors and antioxidant enzymes, and by promoting DNA damage repair.
In this study, we explored the effect of parthenolide on intracellular redox status in
both prostate cancer and normal prostate cells, and investigated how parthenolide
regulates NADPH oxidase, GSH and Trx, and the redox-related PI3K/Akt/FOXO3a
pathway and how they are linked to each other to contribute to the radiosensitization
effect of parthenolide.
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Materials and Methods
Cell culture and treatment. Human prostate cancer cell lines PC3 and DU145 were
obtained from American Type Culture Collection (Manassas, VA) and cultured as
previously described. Human normal prostate epithelial PrEC cells were purchased from
Lonza (Walkersville, MD) and maintained in Prostate Epithelial Cell Growth Medium
(PrEGM, Lonza). All cells were grown in a 5% CO2 atmosphere at 37°C. Parthenolide
stock solution (5 mmol/L) was prepared in DMSO and diluted in culture medium to the
indicated final concentration for cell treatment. DMSO (0.1%) diluted in medium was
used as vehicle control. A 130 kv X-ray machine (Faxitron X-ray Corporation) was used
to radiate cells, with a dose rate of 89.7 cGy/min. NADPH oxidase inhibitor diphenylene
iodonium (DPI, Sigma) and PI3K inhibitor wortmannin (Cell Signaling) were disolved in
DMSO. The final concentrations used to treat cells were 0.5 µmol/L and 1µmol/L
respectively.
MTT assay. Cells were plated into 96-well plates at different densities according to their
plating efficiencies (PC3 cells at 1,000 cells/well, PrEC cells at 5,000 cells/well) and
grew overnight to achieve similar confluence. Then, cells were treated with parthenolide
for 24 hours, and exposed to the indicated dose of radiation or sham-irradiated. Twentyfour hours after radiation, parthenolide-containing medium was replaced with normal
culturing medium so that the total time for parthenolide treatment was 48 hours. After
four cell doubling times [124] (around 4 days for PC3 cells and 8 days for PrEC cells), 3(4,5-methylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide (MTT, 50 μg/well) was
added and incubated at 37°C for 1 hour. After removal of medium, DMSO 200 µL was
added to each well to dissolve the purple formazan crystal. The absorbance was measured
at 540 nm. Cell survival was normalized to the untreated control group.
Cell growth curve. PC3 and PrEC cells were plated into 12-well plates at different
densities according to their plating efficiencies and grew overnight. Cells were treated in
the same way as described above for MTT assay. Twenty-four hours after radiation (day
1), parthenolide-containing medium was replaced with normal culturing medium. Cells
from each well of the triplicates were trypsinized and counted, and the mean number of
cells/well was obtained every other day from the triplicate average. The results were
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plotted on a log-linear scale and fitted into exponential growth curve fit. The growth rate
constant in each treatment group was compared.
DCF assay. Cells were plated into 48-well plates and grew overnight. Twenty-four hours
after parthenolide or DMSO treatment, cells were washed twice with PBS and preloaded
with 20 µmol/L carboxy-H2DCFDA (invitrogen) or the oxidized carboxy-DCFDA
(invitrogen, insensitive to oxidation, used to normalize cell number, as well as uptake,
efflux, and ester cleavage of H2DCFDA) diluted in PBS by incubation at 37°C for 30
minutes. At the end of the incubation period, the cells were again washed twice with PBS,
then irradiated while they were covered with 100 µL PBS per well. After the radiation
exposure, the plates were incubated at 37°C for 20 minutes and read with a Gemini XPS
fluorescence microplate reader at excitation and emission wavelengths of 485 and 528
nm, respectively. The fluorescence level of cells preloaded with carboxy-H2DCFDA was
normalized to that of cells preloaded with carboxy-DCFDA (the ratio of H2DCFDA
/DCFDA) to eliminate the cell number and dye uptake differences between different
treatment groups. The PBS used in this assay was supplemented with 1 mmol/L CaCl2
and MgCl2.
Detection of reduced thiols and disulfides. The protein thiols were labeled by 3-(Nmaleimido-propionyl) biocytin (MPB) and detected by avidin-biotin technology on the
blots as previously described by Bayer et al [125]. Cells were harvested by scraping in
SEE buffer (0.1 mol/L sodium phosphate, pH 7.0, 5 mmol/L EDTA, 5 mmol/L EGTA)
and homogenized with 50 strokes in a Dounce homogenizer on ice. Protein samples were
then treated with 10 μg/mL MPB (Sigma) for 30 minutes and dialyzed for 3 hours.
Samples were kept on ice throughout and dialysis was conducted at 4°C. Labeled
proteins were subjected to SDS-PAGE, followed by detection with HRP-conjugated
streptavidin and ECL® Plus (GE Healthcare). To detect protein disulfides, samples were
first treated with 10 mg/mL N-ethylmaleimide (NEM; Sigma) for 1 hour and dialyzed for
3 hours against PBS. Then 2-mercaptoethanol (ME; Sigma) was added at a final
concentration of 2% (v/v). After 30 minutes incubation, protein was dialyzed overnight
with 3 buffer changes. The NEM-blocked, ME-reduced protein was then treated with
MPB as described above for direct thiol labeling.
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NADPH oxidase activity assay. This assay was performed as described previously by
Cui and Douglas [126]. After treatment, cells were washed and scraped in ice-cold PBS,
and centrifuged at 750×g for 10 minutes. The cell pellet was resuspended in buffer
containing 20 mmol/L KH2PO4, 1 mmol/L EGTA, 1 mmol/L phenylmethylsulfonyl
fluoride and protease inhibitor cocktail, and homogenized with 50 strokes in a Dounce
homogenizer on ice. After determining protein concentration, the homogenate was used
immediately to assay NADPH oxidase activity. To start the assay, 30 µg of homogenate
in 20 µL volume was added into 180 µL reaction buffer (50 mmol/L phosphate buffer,
pH 7.0, containing 1 mmol/L EGTA, 150 mmol/L sucrose, 500 µmol/L luciginin and 500
µmol/L NADPH). Photoemission in terms of RLU was measured by Xenogen IVIS
Spectrum every minute for 15 minutes. The reaction velocity was calculated as the
change of RLU per minute per μg protein. The Km and Vmax values were calcaulated
from the respective Lineweaver-Burk plots by using various concentrations of substrate
NADPH in the assay.
GSH assay. Cells were collected for glutathione assays (total GSH, GSSG, and reduced
GSH levels) using the Glutathione Aassay Kit (Cayman Chemical). Briefly, cell pellets
were homogenized in 500 µL cold PBS buffer, and centrifuged at 10,000 ×g for 15
minutes at 4 °C. The supernatant was measured for protein concentration and then
deproteinated by adding equal volume of the 10% metaphosphoric acid to precipitate
protein. Before the assay, 50 µL of 4 mol/L triethanolamine was added into per mL
supernatant to adjust the pH. For GSSG assay, 100 µL of supernatant was incubated with
1 µL of 1 mol/L 2-vinylpyridine at room temperature for 60 minutes to derivatize GSH.
Total GSH (GSHt) and GSSG were measured using recycling assay involving the
reaction of DTNB (5,5‟-dithio-bis-2-nitrobenzoic acid) and glutathione reductase, and
then normalized to cellular protein level. The amount of reduced GSH was calculated by
subtracting the amount of GSSG from total GSH (GSHt - 2GSSG).
Preparation of whole cell extracts, cytoplasmic and nuclear fractions. Cell pellets
were suspended in 100 µL cell lysis buffer and incubated for 30 minutes on ice. The
samples were then centrifuged at 13,000 rpm for 1 minute. The supernatant was collected
as whole cell extract. Cytoplasmic and nuclear fractions were isolated using the Nuclear
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Extract Kit (Active Motif). Protein concentration was determined by Bradford assay
(Bio-Rad).
Western blot analysis. Western blot analysis was performed as previously described
[108] using corresponding antibodies against Akt, Phospho-Akt (Ser 473), FOXO3a and
Phospho-FOXO3a (Ser 253) (Cell Signaling), actin (Sigma), Nox1 (Santa Cruz), Lamin
A/C (Santa Cruz), catalase (Santa Cruz) and MnSOD (Upstate). Representative blots and
quatification from three independent experiments are shown.
Knocking down Nox1 using siRNA. Cells were plated into 6-well plates, and transiently
transfected with Nox1 siRNA (Santa Cruz, final concentration 80 nmol/L) and control
siRNA

by

using

OligofectamineTM

(Invitrogen,

5µL/well)

according

to

the

manufacturer's instructions.
Electrophoretic mobility shift assay (EMSA). Double-stranded oligonucleotides
corresponding to the MnSOD promoter region containing consensus FOXO3a binding
element

(DBE,

Daf-16

family

protein

binding

element)

[118]

(5'-

32

TTCTGACGTCTGTAAACAAGCCCAGCCCTT-3') were labeled with [ P] ATP. The
assay was performed as previously described [108].
Chromatin immunoprecipitation (ChIP assay). Cells were collected and processed by
using the ChIP-IT kit (Active Motif) after treatment. Briefly, protein/DNA complexes
were fixed, and DNA were sheared using an enzymatic shearing cocktail (200 U/mL) at
37oC for 10 minutes to generate DNA fragments around 150-1000 bp in length. Samples
were precipitated using anti-FOXO3a antibody (Cell Signaling). The DNA was reverse
cross-linked, purified and then analyzed by quantitative PCR. Taq DNA polymerase
(Promega) was used to amplify the MnSOD promoter fragment containing DBE. The
sequences

of

primer

set

were:

CACCCCAACACGTAGCCCTAGTTACATTC-3‟;

upper-strand
and

primer,

lower-strand

primer,

5‟5‟-

CTAGGCTTCCGGTAAGTGGAATGGGAAAAC-3‟.
SOD mimetic treatment and colony survival assay. PC3 cells were trypsinized and
plated in triplicate into 6-well plates at the concentrations of 100 cells/well for the no
radiation treatment group and 200 cells/well for the 4 Gy radiation treatment group.
Parthenolide or DMSO was used to treat cells for 24 hours. SOD mimetic (MnTE-2PyP5+) was added at the same time as parthenolide. Then, the cells were exposed to 4 Gy
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radiation or were sham-irradiated. Twenty-four hours after radiation treatment, the media
containing parthenolide was replaced with growing media with or without SOD mimetic.
Twelve days after the cells were plated, they were washed and stained with crystal violet,
and the colonies containing more than 50 cells were counted. Plating efficiency (PE) was
calculated by dividing the average number of cell colonies per well by the amount of
cells plated. Survival fractions were calculated by normalization to the plating efficiency
of appropriate control groups.
FOXO3a transient transfection and determination of cell survival by trypan blue
exclusion assay. The plasmids HA-FOXO3a WT (wild-type) and HA-FOXO3a TM
(triple mutant) were obtained from Addgene [113]. In HA-FOXO3a TM, the three key
regulatory sites of Akt phosphorylation, Thr32, Ser253, and Ser315, were converted to
alanine such that Akt could no longer phosphorylate these sites. Cells were plated into
12-well plates and transfected with HA-FOXO3a WT, HA-FOXO3a TM expression
plasmids or pECE vector control plasmid, using LipofectamineTM 2000 (Invitrogen)
according to the manufacturer's instructions. Briefly, 1.5 µg plasmid was mixed with 50
µL incomplete medium without fetal bovine serum and then complexed with a mixture of
2.5 µL of Lipofectamine and 50 µL of incomplete medium for 20 minutes at room
temperature. The mixture was diluted with 500 µL of incomplete medium and added to
the cells. After 6 hours, the medium was replaced with 1 mL of complete medium with or
without parthenolide and incubated overnight. Cells were then treated with 6 Gy radiation
or were sham-irradiated. Forty-eight hours after radiation, the cells were processed for
trypan blue exclusion assay and collected for Western blot analysis. Cell suspension (10
µL) was mixed with 10 L 0.04% trypan blue solution and then loaded onto a
hemocytometer. Cells were counted under light microscope. Dead cells retained the dye
while the viable cells excluded trypan blue and appeared bright. The cell survival was
calculated against the relative untreated control group.
Statistical analysis. Statistical analysis was performed using either Student's t test (for
two-group comparison) or one-way ANOVA (for multiple-group comparison). Data were
reported as mean ±SE.
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Results
The radiosensitization effect of parthenolide is selective to prostate cancer PC3 cells
but not normal prostate epithelial PrEC cells.
Previously, we showed that parthenolide synergistically enhances the sensitivity of
prostate cancer cells to radiation treatment using colony survival assay [108]. In the
present study, we compared the effect of parthenolide in prostate cancer PC3 cells and
normal prostate epithelial PrEC cells. Because PrEC cells did not form colony in vitro,
we performed MTT assays. PrEC cells were more resistant to parthenolide-induced
cytotoxicity compared with PC3 cells (Figure 3.1 A). The sub-cytotoxic dose of
parthenolide (1μmol/L) was chosen to study the parthenolide and radiation combination
effect on cell survival. As shown in Figure 3.1 B, radiation 6 Gy decreases cell viability
similarly in PC3 cells (by 53%) and in PrEC cells (by 41%). In the presence of
parthenolide 1μmol/L alone, the viability of PC3 cells is 74.4% of control. When
combined with 6 Gy radiation, cell viability is further decreased to 23.6% of control.
However, 1µmol/L of parthenolide alone does not reduce cell viability in PrEC cells and
does not enhance radiation- induced cytotoxicity. Comparisons of growth curves for these
two cell lines also reveal a selective radiosensitization effect of parthenolide (Figure 3.1
C) in PC3 cells. Radiation 6 Gy decreases cell growth rate by approximately 50% in both
cell lines (Table 3.1). However, in the presence of parthenolide, different effects were
observed in prostate cancer PC3 and noncancerous PrEC cells after radiation. In PC3
cells, parthenolide alone decreases cell number without affecting cell growth rate. A
combination of parthenolide and radiation showed radiosensitization in PC3 cells by both
decreased cell start number and lower growth rate, leading to much fewer cells compared
with the radiation-treated group at 7 days after radiation. In PrEC cells, parthenolide
alone slightly decreases cell number without much change in cell growth rate.
Combination treatment, however, shows a smaller cell start number but the same growth
rate as the control group, leading to similar cell numbers compared with the radiationtreated group at 7 days after radiation, which is consistent with the MTT result after 4 cell
doubling times.
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Parthenolide induces oxidative stress in PC3 cells but not in PrEC cells.
The differential effect of parthenolide in prostate cancer PC3 cells and normal
prostate epithelial PrEC cells led us to investigate the determinant factors for the
selectivity of parthenolide‟s effect. Since oxidative stress has been shown to be the major
mechanism for both parthenolide [43] and radiation induced cell death, we compared the
effect of parthenolide on cellular ROS level in PC3 and PrEC cells by DCF assay. As
shown in Figure 3.2 A, neither parthenolide nor radiation changes the fluorescence in
cells loaded with oxidized carboxy-DCFDA, which means the dye uptake is not affected
by the treatment. Radiation significantly increases the normalized carboxy-H2DCFDA
fluorescence, a general indicator of cellular ROS level, in both PC3 and PrEC cells.
However, parthenolide alone only increases the normalized carboxy-H2DCFDA
fluorescence in PC3 cells but not PrEC cells, indicating parthenolide selectively induces
oxidative stress in prostate cancer PC3 cells but not normal prostate PrEC cells. When
combined with radiation, parthenolide further elevates the cellular ROS level in PC3 cells,
consistent with the radiosensitization effect. Interestingly, in PrEC cells, parthenolide
even decreases radiation-induced ROS level (significant at 5 µmol/L), showing an
antioxidant property.
Parthenolide exerts its effect mainly by targeting Cys thiol groups (-SH) in a Michael
addition reaction, and this direct reaction with the Cys thiols has been shown to lead to
the depletion of intracellular GSH and protein thiols and induction of ROS in some
cancer cells [43, 45]. We therefore detected the protein thiols and oxidized disulfides in
PC3 and PrEC cells by MPB labeling. As shown in Figure 3.2 B, parthenolide 5 µmol/L
significantly decreases the reduced protein thiols and increases the oxidized disulfides
staining in PC3 cells. The decrease in the reduced protein thiols may result from the
direct reaction of parthenolide with protein thiols or the oxidation of thiol groups due to
parthenolide-induced oxidative stress. However, in PrEC cells, parthenolide does not
significantly change the protein thiols and disulfides, which is consistent with the
selective induction of oxidative stress in PC3 cells but not PrEC cells.
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Parthenolide activates NADPH oxidase in PC3 cells but not in PrEC cells.
Oxidative stress is the imbalance between prooxidants and antioxidants. Increases in
the production of ROS and decreases in antioxidants can both lead to oxidative stress.
One of the major sources of ROS generation in prostate cancer cells is the NADPH
oxidase system [32, 109]. Therefore, following parthenolide treatment we measured
NADPH oxidase activity to see whether it is involved in the parthenolide-induced
oxidative stress in prostate cancer PC3 cells. Our results (Figure 3.2 C) show that
parthenolide enhances NADPH oxidase activity dose-dependently in PC3 cells, which
can be inhibited by DPI, a NADPH oxidase inhibitor. However, in normal prostate PrEC
cells, NADPH oxidase activity is not affected by parthenolide treatment, consistent with
the selective induction of oxidative stress in PC3 cells but not PrEC cells. The enzyme
kinetics study (Figure 3.2 D) performed in PC3 cells indicates that parthenolide activates
NADPH oxidase without changing the Vmax but decreasing Km (Table 3.2).

Parthenolide decreases reduced Trx in PC3 cells as a downstream event of NADPH
oxidase activation, but increases GSH in PrEC cells.
Since parthenolide targets thiols, we also analyzed two important thiol-containing
small molecule antioxidants, GSH and Trx. Total GSH and oxidized GSSG levels were
measured after parthenolide, radiation and combination treatment. As shown in Figure
3.3 A, total GSH level is slightly increased in PC3 cells and significantly increased in
PrEC cells after parthenolide treatment. The reduced GSH/GSSG ratio is not significantly
changed by parthenolide in PC3 cells. But in PrEC cells, it is increased 2.4 fold by
parthenolide, which may lead to the protective effect against radiation-induced oxidative
stress we observed in DCF assay. Globally decreased protein thiols were observed in PC3
cells but not in PrEC cells after parthenolide treatment (Figure 3.2 B). We then
specifically looked at reduced Trx, which is the active form of Trx, by using Trx antibody
to pull down the thiol-labeled protein sample. Parthenolide significantly decreases
reduced Trx in PC3 cells without altering the Trx protein amount (Figure 3.3 B).
However, in the presence of DPI, the decrease caused by parthenolide in the reduced Trx
is abolished, suggesting that this is a downstream event of NADPH oxidase activation. It
is likely that Trx was oxidized by NADPH oxidase derived reactive species.
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Activation of NADPH oxidase by parthenolide is upstream of the PI3K/Akt
activation in PC3 cells.
Our previous study found that parthenolide activates the PI3K/Akt pathway in PC3
cells. PI3K/Akt pathway has been known to be activated by growth factors and adhesion
to matrix or other cells. It has also been shown to be activated in response to oxidative
stress [127], so we tested whether the activation of PI3K/Akt pathway is a downstream
event of NADPH oxidase activation in PC3 cells. The PI3K inhibitor wortmannin
1µmol/L prevents the activation of Akt by parthenolide, as indicated by the decrease of pAkt/Akt ratio. However, activation of NADPH oxidase by parthenolide is not affected
(Figure 3.4 A). We then tried to identify the specific subtype of NOX in PC3 cells and
knock down the subtype. We examined the expression of Nox1-5 and Duox1, 2 by realtime PCR and found that PC3 cells expressed the mRNA of Nox1, Nox4, Duox1 and
Duox2. Nox1 is the major Nox isoform in PC3 cells. Knocking down Nox1 by siRNA
inhibits both parthenolide-induced NADPH oxidase activation and Akt activation (Figure
3.4 B), suggesting Nox1-dependent NADPH oxidase activation is upstream of PI3K/Akt
activation by parthenolide. This was further confirmed by using NADPH oxidase
inhibitor, DPI, which can significantly inhibit NADPH oxidase activity as shown in
Figure 3.2 C. In the presence of DPI, Akt activation by parthenolide and the downstream
target of Akt kinase, FOXO3a phosphorylation, are both prevented (Figure 3.4 C).

Activation of Akt by parthenolide induces FOXO3a inhibitory phosphorylation and
suppresses its downstream targets, antioxidant enzymes MnSOD and catalase in
prostate cancer cells, but not in PrEC cells.
FOXO3a is one of the main targets of activated Akt. There are three conserved Akt
phosphorylation sites on FOXO3a: Thr32, Ser253 and Ser315 [128]. Consistent with our
previous study [108], parthenolide increases Akt Ser473 phosphorylation in prostate
cancer PC3 and DU145 cells (Figure 3.5 A). Consequently, the phosphorylation on
Ser253 in FOXO3a is increased by parthenolide in a dose-dependent manner. Radiation
slightly increases both Akt and FOXO3a phosphorylation, but not as dramatically as
parthenolide does. This may be explained by the fact that radiation only induces transient
activation of Akt, as shown by our previous study, which showed that Akt
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phosphorylation peaks at 1 hour after radiation and then drops at 6 hours after radiation
[108]. In DU145 cells, the total FOXO3a level is increased after radiation treatment,
consistent with Yang‟s observation in osteosarcoma cells [120]. Parthenolide treatment
decreases total FOXO3a level in DU145 cells, which may be due to Akt activationinduced FOXO3a degradation by proteasome [129]. While FOXO3a phosphorylation
increases in prostate cancer cells, in normal prostate epithelial PrEC cells, the
combination of parthenolide with radiation does not enhance but slightly decreases
FOXO3a phosphorylation.
Akt-mediated phosphorylation has been known to induce FOXO3a relocalization
from the nucleus to the cytoplasm. To verify whether parthenolide-induced FOXO3a
phosphorylation would affect FOXO3a nuclear-cytoplasmic shuttling, we isolated cell
nuclear fractions after parthenolide and radiation treatment. Nuclear protein Lamin A/C
was used as markers for nuclear fraction. Our data (Figure 3.5 B) show that in both PC3
and DU145 cells, nuclear FOXO3a level is increased at 6 hours after radiation treatment,
in spite of radiation-induced Akt-mediated inhibitory phosphorylation of FOXO3a
(Figure 3.5 A). This might be due, in part, to the fact that radiation also activates JNK
[16], which can induce activatory phosphorylation of FOXO3a. Parthenolide induces
FOXO3a phosphorylation and decreases nuclear FOXO3a levels in both cell lines (Figure
3.5 B). In PC3 cells, as FOXO3a is excluded from nucleus, more FOXO3a is detected in
the cytoplasmic fraction after parthenolide treatment, consistent with the stable FOXO3a
level in PC3 whole cell lysate (Figure 3.5 A). However, in DU145 cells, as the FOXO3a
level in whole cell lysate is decreased by parthenolide treatment, we observe a decrease
in FOXO3a level both in nuclear and cytoplasmic fraction.
FOXO3a is a transcription factor which binds DNA at the consensus sequence DBE
(5'-TTGTTTAC-3') [130]. It has been shown that radiation can increase FOXO3a
transcriptional activity [120], which depends not only on the level of FOXO3a available
in the nucleus, but also on its DNA binding activity. We then detected the DNA binding
activity of FOXO3a after parthenolide treatment. Using gel mobility shift assay, we
found that radiation enhances FOXO3a DNA binding activity in PC3 cells. Parthenolide
inhibits FOXO3a DNA binding dose-dependently (Figure 3.5 C). However, parthenolide
does not change FOXO3a DNA binding activity in PrEC cells. To verify that FOXO3a
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indeed binds to the promoter of its target gene, we also performed a chromatin
immunoprecipitation assay using anti-FOXO3a antibody to pull down the DNA protein
complex. We found that radiation enhances FOXO3a binding to the MnSOD promoter
region containing the FOXO3a consensus sequence (Figure 3.5 C). In the presence of
parthenolide, FOXO3a binding at the MnSOD promoter is suppressed, consistent with
the EMSA result. Our data suggest that FOXO3a DNA binding activity is reduced by
parthenolide because of the decreased nuclear FOXO3a level.
FOXO3a has been shown to regulate a wide range of target genes involved in cell
cycle arrest, apoptosis, stress response and DNA repair. Since radiation kills cells largely
through inducing oxidative stress, we detected FOXO3a targets, antioxidant enzymes
catalase and MnSOD, in prostate cancer PC3 and DU145 cells (Figure 3.5 D). MnSOD
protein level was increased 24 hours after radiation treatment in both cell lines, but was
suppressed by parthenolide. Parthenolide also decreases catalase levels dose-dependently
in both cell lines. Consistent with FOXO3a DNA binding activity, MnSOD and catalase
protein levels are not changed by parthenolide in PrEC cells.

Suppression

of

antioxidant

enzymes

by

parthenolide

contributes

to

its

radiosensitization effect.
The suppression of antioxidant enzymes by parthenolide in prostate cancer cells may
contribute to the induction of oxidative stress and the selective radiosensitization effect of
parthenolide. To confirm the role of antioxidant enzymes in the selective
radiosensitization effect of parthenolide, we treated PC3 cells with an antioxidant SOD
mimetic, MnTE-2-PyP5+. As shown in Figure 3.6 A, the survival fraction of PC3 cells
treated with 4 Gy radiation in combination with 1.0 µmol/L parthenolide is 0.25, which is
significantly lower than the survival fraction of cells treated with 4 Gy radiation or 1.0
µmol/L parthenolide alone. However, the survival fraction increases to 0.39 in the
presence of SOD mimetic. SOD mimetic reduces the radiosensitization effect of
parthenolide in PC3 cells, confirming the role of antioxidants in the radiosensitization
effect of parthenolide.
We then overexpressed FOXO3a in PC3 cells to investigate whether overexpression
of FOXO3a can rescue cells from parthenolide-induced radiosensitization effect by

57

induction of antioxidant enzymes. We used two FOXO3a expression plasmids, HAFOXO3a WT and HA-FOXO3a TM, which bears three mutations at the Akt
phosphorylation sites leading to a constitutively active FOXO3a. Cell survival was
determined 48 hours after radiation and parthenolide treatments. Overexpression of
FOXO3a WT and FOXO3a TM decreases survival of untreated cells, possibly due to the
induction of apoptotic targets of FOXO3a [119]. To better compare the effect of radiation
and parthenolide in FOXO3a-overexpressing cells and empty vector transfected cells, we
normalized all untreated cell viability to 100% to eliminate the basal survival differences
among three different transfection groups. After normalization, we observed that
FOXO3a overexpression does not significantly affect cell sensitivity to radiation
treatment. However, compared with the cells transfected with vector control,
overexpression of FOXO3a WT slightly increases cell survival after parthenolide
treatment alone and combined treatment. Overexpression of constitutively active
FOXO3a TM in PC3 cells significantly confers cellular resistance to parthenolide‟s effect
(Figure 3.6 B). The expression of exogenous HA-FOXO3a was confirmed by Western
blot. Consistent with the role of FOXO3a, the basic levels of antioxidant enzymes,
catalase and MnSOD are higher when active FOXO3a TM is overexpressed (Figure 3.6
C). These data demonstrate that FOXO3a plays an important role in maintaining cellular
antioxidant enzymes, catalase and MnSOD, that are involved in the radiosensitization
effect of parthenolide.

Discussion
Parthenolide has been shown to cause cell death in acute myelogenous leukemia
(AML) cells and prostate cancer stem cells without affecting hematopoietic stem cells
(HSC) and normal prostate stem cells [46, 131], suggesting the selectivity of its cytotoxic
effect to cancer cells. Consistent with this finding, in the present study, we found that
normal prostate epithelial PrEC cells are more resistant to parthenolide-induced
cytotoxicity compared with prostate cancer PC3 cells. Furthermore, the radiosensitization
effect of parthenolide, which we discovered in our previous study [108], is selective to
prostate cancer cells but not normal prostate epithelial PrEC cells, as shown by MTT and
cell growth assays (Figure 3.1). Our results also indicate that parthenolide “rejuvenates”
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irradiated normal prostate cells since the cell growth rate after radiation is restored to the
untreated control level when combined with parthenolide treatment. This suggests that
parthenolide may facilitate repair of radiation-induced damage in normal cells. However,
the possible mechanisms involved need to be further investigated.
The selective targeting of cancer cells by parthenolide is of great interest. Cancer cells
and normal cells have a different redox status, which may be targeted for selective cancer
killing. Parthenolide has been shown to induce oxidative stress in a number of cancer
cells [43, 46]. We therefore investigated whether the selective effect of parthenolide on
cancer cells is due to differential regulation of intracellular redox status in cancer and
normal cells. Our data show parthenolide selectively induces oxidative stress in prostate
cancer PC3 cells but not normal prostate PrEC cells (Figure 3.2). When combined with
radiation, parthenolide further increases ROS levels in PC3 cells, while it slightly
decreases radiation-induced oxidative stress in PrEC cells. This may explain the selective
radiosensitization effect of parthenolide in PC3 cells and the “rejuvenation” of irradiated
PrEC cells.
NADPH oxidase is a major source of ROS in prostate cancer cells [32]. Several
studies have shown a variable expression profile of the seven Nox family members
(Nox1-5, Duox1, 2) in prostate cancer cells. A study by Arnold and colleagues using a
National Cancer Institute (NCI) prostate cancer tissue microarray (CPCTR) showed that
prostate tumor is significantly more likely (86%) to have Nox1 staining than benign
prostate tissue (62%) [109, 132]. Our results also show Nox1 is the major Nox isoform in
PC3 cells. Parthenolide activates NADPH oxidase in PC3 cells but not in PrEC cells
(Figure 3.3), consistent with the selective induction of oxidative stress in prostate cancer
cells. The enzyme kinetic constant Vmax, which is the maximal velocity available from
the amount of enzyme in the reaction mixture, is not changed by parthenolide. Since
Vmax is directly proportional to the catalytic constant of the enzyme (Kcat), which
describes the frequency at which the enzyme-substrate complex is converted to product,
and the total enzyme concentration ([E]), these data suggest that the amount of enzyme is
not inceased when parthenolide activates NADPH oxidase. This is confirmed by Western
blot, as shown in Figure 3.4 B. However, the Michaelis constant Km, which is the
substrate concentration at which the reaction rate reaches half of Vmax, is decreased
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approximately 50% by parthenolide (Table 3.2), suggesting that parthenolide may
increase the affinity of NADPH oxidase for the substrate NADPH or increase the stability
of the enzyme-substrate complex. The fully activation of Nox1 requires the p22phox,
Noxo1, Noxa1 and Rac1 [110]. Parthenolide may facilitate the assembly of the
multisubunit enzyme complex and thus promote substrate binding. Further study is
needed to determine how parthenolide activates NADPH oxidase.
Parthenolide is a sesquiterpene lactone, which can react with biological nucleophiles
such as the thiol groups via a Michael addition reaction. The depletion of intracellular
GSH and protein thiols by parthenolide may contribute to the induction of oxidative
stress in some cancer cells [43, 45]. In contrast to this possibility, our data show
parthenolide increases intracellular GSH level, especially in PrEC cells (Figure 3.3). This
is possibly due to the activation of the Nrf2/ARE (antioxidant/electrophile response
element) pathway [64]. The increase of GSH may partially account for the antioxidant
activity of parthenolide observed in PrEC cells. Since the reactivities of thiol groups are
inversely related to their pKa, it is reasonable to assume that parthenolide more readily
reacts with certain protein thiols which have low pKa than with GSH which has a high
pKa of 8.8. Parthenolide decreases reduced protein thiols globally in PC3 cells but not in
PrEC cells (Figure 3.2). This may due to the direct reaction of parthenolide with protein
thiols or the oxidation of reduced thiols by parthenolide-induced oxidative stress. For an
example, parthenolide decreases reduced thioredoxin (Trx), an important intracellular
antioxidant, as a result of oxidation by NADPH oxidase derived ROS (Figure 3.3).
Thioredoxin (Trx) has a redox-active dithiol within the conserved active site: -Trp-Cys32Gly-Pro-Cys35-Lys- [133]. The Trx/TrxR system has multiple functions in cell growth,
defense against oxidative stress, and apoptosis [134]. Overexpression of Trx protects
cells not only from oxidative stress-induced apoptosis [135], but also from cytotoxic and
DNA-damaging effects of many chemotherapeutic drugs [136]. Since thioredoxin is an
important intracellular redox buffering system and its proper function depends on the
redox-sensitive cysteine thiol at its active site, decrease of reduced thioredoxin by
parthenolide will likely sensitize cancer cells to oxidative stress induced cell death.
In addition to direct oxidative damage, NADPH oxidase derived ROS plays an
important role in redox signaling due to its highly regulated activation. We have
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previously found that parthenolide activates the PI3K/Akt [108], an oxidative stress
responsive pathway [127]. In the present study, we further demonstrate that the activation
of NADPH oxidase is upstream of PI3K/Akt activation (Figure 3.4). The oxidation and
inactivation of phosphatases that directly dephosphorylate PI3K or AKT kinase by
NADPH oxidase-derived ROS may contribute to PI3K/Akt activation. As a downstream
target of Akt kinase, FOXO3a is phosphorylated and excluded from the nucleus by
parthenolide treatment, and the transcriptional activity of FOXO3a is suppressed by
parthenolide in prostate cancer cells (Figure 3.5). FOXOs have been implicated as
important mediators of cellular response to oxidative stress. Silencing FOXO3a results in
defective ionizing radiation-induced G1/S and G2/M checkpoints [121]. In addition to
inducing cell cycle arrest in response to oxidative stress, FOXO3a mediates the
detoxification of ROS by upregulation of antioxidant proteins, such as MnSOD, catalase,
peroxiredoxin III (Prx III) and sestrin 3 [112, 118, 137, 138]. DNA damage repair is also
triggered by the capability of FOXO3a to induce the transcription of Gadd45a, which is
involved in the maintenance of genomic stability and DNA repair [139, 140]. Recently,
Tsai and colleagues reported that FOXO3a can promote DNA repair in a transcriptionindependent manner. They showed that exposure of LNCaP prostate cancer cells to
ionizing radiation leads to direct interaction of FOXO3a and ataxia telangiectasia mutated
(ATM) protein, resulting in autophosphorylation of ATM on Ser1981 and prompting the
repair of damaged DNA [121]. Based on the capabilities of FOXO3a to induce cell cycle
arrest, stress resistance and DNA repair, our observation that parthenolide inhibits
FOXO3a function by phosphorylation and nuclear exclusion suggests that suppression of
FOXO3a may contribute to the radiosensitization effect of parthenolide. This possibility
is supported by the finding that overexpression of constitutively active FOXO3a
abolishes the radiosensitizing effect of parthenolide. Our data show that FOXO3a
transcriptional targets, antioxidant enzymes MnSOD and catalase, are downregulated by
parthenolide (Figure 3.5). MnSOD is a mitochondria antioxidant enzyme that removes
superoxide radicals. Inhibition of MnSOD expression by antisense MnSOD or selective
inhibition of RelB can enhance radiosensitivity of prostate cancer cells [23, 24]. It is well
established that MnSOD is a FOXO3a target [118] and also a NF-κB target [141]. Our
previous study showed that the NF-κB pathway is inhibited by parthenolide. Thus, it is
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likely that both NF-κB and FOXO3a are contributors to the suppression of radiationinduced MnSOD expression by parthenolide. Further study is needed to investigate
whether these two transcription factors cooperate with each other or act independently in
response to oxidative stress. Catalase is a FOXO3a target with a number of DBEs
between -2339 and -1667 of the promoter [137]. It is a ROS scavenger which reduces
hydrogen peroxide to water. Mitochondria-targeted catalase overexpression has been
shown to increase the survival of irradiated human pancreatic cancer cells [142],
suggesting a role for catalase in protecting cells against radiation-induced cell death.
Overexpression of constitutively active FOXO3a renders PC3 cells more resistant to a
parthenolide-induced radiosensitization effect by up-regulating its targets MnSOD and
catalase (Figure 3.6), confirming the role of FOXO3a in promoting cellular antioxidant
defense.
To summarize, our present study demonstrates that in prostate cancer cells,
parthenolide induces dramatic oxidative stress via NADPH oxidase activation. On one
hand, NADPH oxidase activation by parthenolide increases ROS generation. The
NADPH oxidase derived ROS may decrease reduced Trx or act as a second messenger to
activate the PI3K/Akt/FOXO3a pathway, leading to a decrease in antioxidant defense
capacity. On the other hand, parthenolide increases GSH levels but does not activate
NADPH oxidase in normal prostate epithelial cells. Thus, the selective induction of
oxidative stress by parthenolide in prostate cancer cells accounts for the selective
radiation sensitization effect of parthenolide. Our results also imply that modulating
intracellular redox state might be an ideal way to achieve selective cancer killing in
cancer therapy.
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Figure 3.1 The radiosensitization effect of parthenolide is selective to prostate
cancer PC3 cells but not normal prostate epithelial PrEC cells.
A. MTT assay. PC3 and PrEC cells were treated with indicated concentrations of
parthenolide for 48 hours. Cell viability was measured by MTT assay and normalized to
untreated control after four cell doubling times.
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B. The combination effect of parthenolide and radiation on cell viability was compared in
PC3 and PrEC cells by MTT assay after four cell doubling times as described in
Materials and Methods. * p<0.05 compared with DMSO treated control.
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C. Cell growth curve. The cell numbers from triplicate samples were plotted on a loglinear scale as mean ± SE. Equations derived from exponential growth curve fit
[Y=Start*exp(K*X)] are shown for each growth curve. Cell number begins at Y=Start
and increases exponentially with rate constant K.
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Table 3.1 Comparison of the growth rate constant in PC3 and PrEC cells after
parthenolide and radiation treatment.
The growth rate constant K was obtained from the exponential growth curve fit of the
two cell lines (Figure 3.1 C) and normalized to their relative DMSO treated control
groups.
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Figure 3.2 Parthenolide induces oxidative stress in PC3 cells, but not in PrEC cells.
A. DCF assay. Cells were first treated with parthenolide or DMSO for 24 hours, and then
preloaded with carboxy-DCFDA (insensitive to oxidation) or carboxy-H2DCFDA
(sensitive to oxidation) in PBS and irradiated. After 20 minutes incubation, the plates
were read. Normalized carboxy-H2DCFDA (the ratio of carboxy-H2DCFDA/carboxyDCFDA) was compared.

# p<0.05 compared with no radiation control. * p<0.05

compared with DMSO treated no radiation control. § p<0.05 compared with indicated
group.
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B. detection of protein thiols and disulfides. PC3 and PrEC cells were treated with
DMSO or parthenolide (5 µmol/L) for 24 hours. Then cells were harvested for thiols and
disulfides labeling by MPB as described in Materials and Methods. Labeled protein thiols
were then separated by SDS-PAGE and detected by HRP-streptavidin. 1. DMSO; 2. PN 5
µmol/L.
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C. NADPH oxidase activity assay. Cells were treated with DMSO or parthenolide for 24
hours in the absence or presence of 0.5 μmol/L DPI. Cell homogenates were then
collected and used for analysis. Photoemission generated by the reaction of superoxide
radical and lucigenin were monitored every minute for 15 minutes. The reaction velocity
(V) was calculated as the change of RLU per minute per μg protein. * p<0.05 compared

v (RLU/min /µg protein)

with DMSO treated no DPI control. # p<0.05 compared with no DPI control.
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D. Lineweaver-Burk plot of NADPH oxidase activity in PC3 cell. The reciprocal of the
enzymatic reaction velocity (1/V) was plotted against the reciprocal of the substrate
concentration (1/[NADPH]) as a straight line with y-intercept equivalent to 1/Vmax and
x-intercept representing -1/Km. Equations derived from Lineweaver-Burk equation of
enzyme kinetics 1/V = (Km/Vmax) * (1/[S]) +1/Vmax are shown for each treatment
group.
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Table 3.2 The Vmax and Km of NADPH oxidase in PC3 cells after parthenolide
treatment.
The enzyme kinetic constants Vmax and Km of NADPH oxidase in PC3 cells were
obtained from the Lineweaver-Burk plot (Figure 3.5 B).
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Figure 3.3 Effect of parthenolide on thiol-containing antioxidants GSH and Trx.
A. GSH assay. PC3 and PrEC cells were treated with DMSO or parthenolide (5 µmol/L)
for 24 hours. Then cells were sham-irradiated or subjected to 6 Gy radiation (IR). Cells
were harvested at 24 hours after radiation for GSH detection. * p<0.05, **p<0.001
compared with DMSO control.
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B. Detection of reduced Trx (TRXre) by immunoprecipitating MPB labeled protein
sample with Trx antibody, followed by avidin detection.
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Figure 3.4 Activation of NADPH oxidase by parthenolide is upstream of PI3K/Akt
activation in PC3 cells.
A. PI3K inhibitor wortmannin does not suppress parthenolide-induced NADPH oxidase
activation. PC3 cells were treated with DMSO or parthenolide for 24 hours. Wortmannin
(1 µmol/L) was added 1 hour before and throughout the parthenolide or DMSO treated
period. Then cell homogenates were collected for NADPH oxidase activity measurement
and Western blot analysis. * p<0.05 compared with indicated groups.
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B. Knocking down Nox1 suppresses parthenolide-induced NADPH oxidase activation
and Akt activation. Control siRNA and Nox1 siRNA were transfected into PC3 cells.
Cells were then treated with DMSO or parthenolide for 24 hours and collected for
NADPH oxidase activity measurement and Western blot analysis. * p<0.05 compared
with indicated groups.

NADPH oxidase activity
v (RLU/min/µg protein)

250

*

200

*

150
Ctrl si
100

NOX1 si

50
0
DMSO

PN 1µM

PN 5µM

p-AKT
AKT

p-AKT/AKT

1

1.72

1.78 0.12 0.17 0.00

NOX1
actin
PN (M)

0

1
5
Ctrl siRNA

76

0

1
5
NOX1 siRNA

C. NADPH oxidase inhibitor DPI suppresses parthenolide-induced Akt activation and
FOXO3a phosphorylation. PC3 cells were treated with DMSO or parthenolide for 24
hours in the absence or presence of 0.5 μmol/L DPI. Then cell homogenates were
collected for Western blot analysis.
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Figure 3.5 Activation of Akt by parthenolide induces FOXO3a inhibitory
phosphorylation and suppresses its downstream targets, antioxidant enzymes
MnSOD and catalase in prostate cancer cells, but not in PrEC cells.
A. Cells were treated with DMSO or parthenolide for 24 hours before being subjected to
6 Gy radiation. Whole cell lysates were prepared 6 hours after radiation for Western blot
analysis.
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B. Western blots anaylsis of cytoplasmic and nuclear fractions.
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C. Detection of FOXO3a DNA binding activity by EMSA and ChIP assay. Cells were
treated with DMSO or parthenolide for 24 hours before IR. Six hours after radiation, cells
were processed for EMSA or ChIP assay. For ChIP assay, input samples were prepared
for each group before adding antibodies as an indicator of the samples input. Anti-RNA
polymerase II antibody was used and GAPDH promoter region was amplified as negative
control.

PC3

PrEC

DMSO PN 1M PN 5M

DMSO PN 1M PN 5M

FOXO3a

input
1

2

3

IP
4

1

2

IgG H2O
3

4

MnSOD promoter
132 bp

IP: FOXO3a

GAPDH promoter
166 bp

IP: RNA pol II
1.
2.
3.
4.

DMSO
IR 6 Gy
PN 5 M
PN 5 M + IR 6 Gy

80

D. Cells were treated with DMSO or parthenolide for 24 hours before being subjected to
6 Gy IR. Whole cell lysates were prepared 24 hours after radiation for Western blot
analysis.
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Figure 3.6 Suppression of antioxidant enzymes by parthenolide is involved in its
radiosensitization effect.
A. SOD mimetic partially abolishes the radiosensitization effect of parthenolide in PC3
cells. Colony survival assay was performed with SOD mimetic in PC3 cells as described
in Materials and Methods. * p<0.05 compared with untreated control. ** p<0.05
compared with PN alone and radiation alone. # p<0.05 compared with PN in combination
with radiation.
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B. Overexpression of FOXO3a protects PC3 cells against the effect of parthenolide. PC3
cells were transiently transfected with pECE vector control, HA-FOXO3a WT or HAFOXO3a TM expression plasmids. Parthenolide was added to the medium. Cells were
grown overnight, then treated with 6 Gy radiation or were sham-irradiated. After 48
hours, the cells were processed for trypan blue exclusion assay and collected for Western
blot analysis. Both unnormalized and normalized cell viability are shown. * p<0.05
compared with pECE vector control plasmid transfected cells under the same treatment
condition.
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C. Western blots to confirm overexpression of FOXO3a in PC3 cells.
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Figure 3.7 Summary of chapter three

Prostate Cancer Cells

NADPH
oxidase

Normal Prostate Cells

IR

IR
TRXre

Nrf2?

PI3K
AKT
P P P
FoxO3a

GSH

ROS

ROS
MnSOD,

MnSOD,

FoxO3a

catalase

FoxO3a

NF-κB

NF-κB

Copyright © Yulan Sun 2010

85

catalase

Chapter Four
Summary and overall discussion

Overcoming treatment resistance and improving selectivity are two major challenges
in cancer treatment. Better understanding of cancer cell characteristics and the
mechanisms for the development of resistance will help us to target cancer cells more
efficiently and more selectively. Elevated oxidative stress and aberrant redox homeostasis
are frequently observed in cancer cells compared to their normal cell counterparts.
Persistent high ROS in cancer cells often leads to adaptive responses which include the
upregulation of antioxidants, inhibition of apoptosis and increased cell proliferation. Such
adaptive responses may contribute to tumorigenesis, metastasis and treatment resistance.
I hypothesize that modulating cell redox status and the redox-related signaling pathway
may be an ideal way to kill cancer cells selectively. The study presented here is a good
example in support of this hypothesis. Our data demonstrate that parthenolide regulates
prostate cancer cell redox status through multiple mechanisms, including both induction
of ROS generation and inhibition of the antioxidant defense system. The differential
modulation of intracellular redox status by parthenolide in cancer and normal prostate
cells leads to the selective radiosensitization effect of parthenolide. This study confirms
that modulating cell redox status is an efficient and selective way to kill cancer cells, and
identifies parthenolide as such an agent.

Parthenolide enhances radiation sensitivity in prostate cancer cells through multiple
mechanisms
The sensitivity of cancer cells to radiation treatment is determined by numerous
factors. For example, the activation of oncogene Ras [143] and some prosurvival
pathways such as the PI3K/Akt, NF-κB pathway increases radiation resistance. DNA
damage repair capacity is also correlated with radiation sensitivity. Since induction of
oxidative stress is an important mechanism for radiation induced cell killing, cancer cells
may exhibit radiation resistance as a result of adaptive response to the increased intrinsic
ROS level in cancer cells or the exogenous ROS derived from radiation. Thus, a
combination of radiotherapy with some agents that modulate the intracellular redox status
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in cancer cells will theoretically exacerbate the oxidative stress induced by radiation and
enhance radiosensitivity. Although other mechanisms may also be involved, our study
focused on how parthenolide modulates cell redox status, leading to the induction of
oxidative stress and radiosensitization effect.
1) Parthenolide suppresses radiation induced NF-κB activation and its downstream
target, antioxidant enzyme MnSOD induction, in prostate cancer cells. NF-κB is a redox
sensitive transcription factor, which is activated by radiation through either the nuclear or
the cytoplasmic pathway [144]. The nuclear pathway depends on the ATM activation
induced by DNA damage. The cytoplasmic pathway may involve the ROS-mediated NIK
(NF-κB-inducing kinase) or PI3K/Akt activation. The NF-κB downstream targets are
involved in cell cycle regulation (such as cyclin B1, cyclin D1), prevention of apoptosis
[such as XIAP (X-chromosome-linked inhibitor of apoptosis), Bcl-XL], DNA damage
repair [such as GADD45β (growth arrest and DNA damage-inducing protein β) and Ku],
and detoxification of ROS (such as MnSOD). It has been shown that MnSOD is critical
in the radiation-induced adaptive response, which not only acts as an antioxidant, but also
mediates the expression of genes that participate in radiation-induced adaptive responses
[23]. Previous studies from our lab demonstrated that using p100 mutant, RelB siRNA
[24], SN52 [145] or 1,25-dihydroxyvitamin D3 [146] can suppress RelB-mediated
MnSOD expression and sensitize prostate cancer cells to radiation. The present study
demonstrates that parthenolide is an effective NF-κB inhibitor that suppresses MnSOD
induction and mediates the radiosensitization effect. In addition to MnSOD, other NF-κB
targets may also be involved in the radiosensitization effect of parthenolide. Watson et al.
reported that suppression of radiation-induced NF-κB activity by parthenolide leads to
the radiosensitization through inhibition of split-dose repair [147], implying that NF-κB
targets related to cell cycle progression and DNA damage repair are also involved.
2) Parthenolide activates NADPH oxidase, which is an important source of ROS and
can mediate redox signaling. The NOX protein is a transmembrane protein. The
subcellular localization of NOX protein includes plasma membrane, nuclear membrane,
endosome and endoplasmic reticulum [148]. Therefore, the NOX can generate ROS both
extracellularly and intracellularly. The superoxide radical generated by NADPH oxidase
is short-lived and highly reactive, and due to its negative charge, it is unable to cross the
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membrane. The hydrogen peroxide derived from superoxide radical is more stable and
can cross biological membranes freely, so it is more important in NOX-dependent redox
signaling transduction. Due to the short-lived nature and the limited diffusion distance of
ROS, it is speculated that the production of ROS by NOX is localized and can only
modulate the redox-sensitive targets in its proximity, for example inactivation of
phosphatases or activation of kinases. Our study shows that parthenolide induced
NADPH oxidase activation is upstream of PI3K/Akt activation. Both the NOX1 protein
[149] and PI3K kinase [150] has been reported to be located in the caveolae, where
numerous signaling molecules are concentrated. Thus, the caveolae may be a platform
where NOX initiates downstream signaling. The mechanism by which parthenolide
activates NADPH oxidase needs further investigation. Our data show that parthenolide
may increase the affinity of NADPH oxidase with its substrate, NADPH. One possibility
is that parthenolide increases the NADPH oxidase complex assembly. The activation of
NADPH oxidase needs the activation of Rac1, which is a member of the Ras superfamily
of GTPases. It has been shown that the modulation of the cysteine thiol can activate Ras
[151, 152]. It is possible that parthenolide may modify the cysteine thiol on Rac1 and
increase its activity.
3) Parthenolide globally decreases reduced protein thiols (-SH) in cancer cells;
specificaly, it markedly decreases reduced thioredoxin as a downstream event of NOX
activation. Protein thiols often play an important role in redox signaling transduction.
Thioredoxin catalyzes the reduction of protein disulfides to thiols, thus maintaining their
proper function. One critical pathway regulated by Trx is the Ref-1/AP-1 pathway. Ref-1
(protein redox factor-1) functions as an apurinic (apyrimidinic) endonuclease to repair
DNA damage, and to regulate the DNA binding activity of several nuclear transcription
factors, including AP-1. In response to radiation, Trx has been shown to translocate into
the nucleus and interact with Ref-1 to activate AP-1 DNA binding activity [153], which
then initiates the protective or reparative responses to the damaging effects of radiation.
Whether a decrease of the reduced form of Trx by parthenolide sensitizes cancer cells to
radiation by interrupting the Ref-1/AP-1 signal needs further study.
4) The activation of NADPH oxidase by parthenolide leads to the activation of
PI3K/Akt kinase and the inhibitory phosphorylation of FOXO3a. Antioxidant enzymes
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MnSOD and catalase are inhibited as a result of the suppression of the FOXO3a
transcriptional function. Our data show that both NF-κB and FOXO3a contribute to the
inhibition of the antioxidant enzyme MnSOD. NF-κB may play a more important role
because NF-κB is constitutively active in most tumor cells, while FOXO3a activity is
usually low in aggressive tumor cells. Our screening by real-time PCR of 12 putative
FOXO3a targets (Table 4.1) in PC3 cells that are involved in stress response and DNA
repair (reviewed from [118, 119, 137-139, 154]) has identified SEPP1 (selenoprotein P)
and FEN1 (flap structure-specific endonuclease 1) (Figure 4.1) as also being targets of
parthenolide, in addition to the two-well established FOXO3a targets, MnSOD and
catalase. Consistent with MnSOD protein level, SOD2 mRNA levels are induced 1.5 fold
after radiation treatment. In the presence of parthenolide, induction by radiation is
completely suppressed. Radiation slightly increases the mRNA levels of antioxidant
protein SEPP1 and DNA repair enzyme FEN1, but the increase is not significant.
Parthenolide significantly decreases the mRNA levels of CAT, SEPP1 and FEN1
compared with radiation-treated group by approximately 20%, 70% and 30%,
respectively. Selenoprotein P is predominantly an extracellular protein containing
10 selenocysteines. It reduces phospholipid hydroperoxide in a manner similar to Gpx
(Glutathione peroxidase) using thioredoxin as the preferred electron donor [155, 156].
Tran et al. identified selenoprotein P as a FOXO3a target [139]. Kabuyama reported that
selenoprotein P suppresses lipid hydroperoxide both inside and outside the
myofibroblasts and functions as an anti-apoptotic factor against oxidative stress [157].
The phospholipid bilayer of cell membranes is susceptible to attack by the radicals
generated following the interaction of water with radiation [158]. The resulting lipid
hydroperoxides and lipid hydroperoxide breakdown products (e.g., α, β unsaturated
aldehydes) contribute to altered plasma membrane lipid composition and cell damage.
Inhibition of SEPP1 by parthenolide may exacerbate the damage of cell membrane
following ionizing radiation, leading to radiosensitization. FEN1 is a structure-specific
nuclease which recognizes and cleaves 5‟ overhang or flap DNA structures. Exposure of
DNA to ROS causes the formation of several different lesions, including oxidized AP
sites. The altered sugar phosphate backbone prevents base excision repair (BER) at the
AP site. FEN1 promotes the repair of an oxidized AP site generated by -irradiation by
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5.1 fold through cleavage of an intermediate reaction generated by template strand
displacement during gap-filling [159]. The inhibition of FEN1, a putative FOXO3a target
[154] by parthenolide, may lead to accumulation of oxidized DNA damage and promote
radiation-induced cell death. Our combined data demonstrate that suppression of
FOXO3a by parthenolide mainly affects proteins involved in oxidative defense and repair
of oxidative DNA damage through transcriptional suppression.

Selective targeting cancer cells by parthenolide
Parthenolide has been previously shown to induce cell death in hepatoma cells,
leukemia cells and prostate cancer stem cells while sparing normal liver cells,
hematopoietic cells and normal prostate stem cells [43, 46, 131]. However, the
mechanisms involved in its selective cytotoxicity to cancer cells remain unknown. Our
study confirms the results of others by showing that the radiosensitization effect of
parthenolide is selective to prostate cancer cells. Our data extend to demonstrate that
parthenolide selectively induces oxidative stress in prostate cancer cells but not in normal
prostate cells. The inhibition of the NF-κB pathway (Figure 4.2), activation of NADPH
oxidase, suppression of FOXO3a transcription function, and the inhibition of antioxidant
enzymes MnSOD and catalase are all observed only in the prostate cancer cells PC3 but
not in the normal prostate cells PrEC. More interestingly, parthenolide can even partially
protect normal prostate cells from radiation-induced oxidative stress and recover the
growth rate of irradiated cells, showing some protective effect to the normal cells.
The possible mechanisms for the differential effect of parthenolide in cancer and
normal cells may involve:
1) Cancer cells including prostate cancer cells usually have constitutively activated
NF-κB, which is involved in cancer growth and treatment resistance, compared to normal
tissue. Therefore, cancer cells are more sensitive to parthenoldie-induced NF-κB
inhibition than normal cells are, which have relatively low NF-κB. In our cell model,
prostate cancer cells DU145 and PC3 have higher levels of NF-κB members compared to
normal prostate PrEC cells (Figure 4.3). Gu et al. showed that parthenolide specifically
inhibits the growth of antiestrogen-resistant breast cancer cells with high NF-κB activity,
but not antiestrogen-responsive cells with low NF-κB activity [160].
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2) Normal prostate cells have higher antioxidant capacity compared with prostate
cancer cells, including the major antioxidant enzymes catalase and MnSOD, and also
GSH content (Figure 4.4). Since induction of oxidative stress is the major mechanism for
the effect of parthenolide, cellular antioxidant status will likely affect sensitivity to
parthenolide. Wang et al. found that in catalase-knockdown multiple myeloma (MM)
cells, parthenolide induces more cell death compared with wild-type MM cells [161],
which is consistent with our speculation that cells with higher antioxidant capacity are
more resistant to parthenolide.
3) Parthenolide may differently affect GSH level in cancer and normal cells. A
previous study by Wen et al. showed that parthenolide depletes GSH in hepatoma cells
but increases GSH in normal liver cells [43]. The reactivities of thiols are related to their
pKa and abundance. The pKa of the cysteine in GSH is as high as 8.8, so it is usually less
reactive. GSH is the most abundant thiol in a cell, so parthenolide may conjugate with
GSH inside the cell. However, due to the much higher concentration of GSH inside cells
compared to the parthenolide concentration we used, it is unlikely that parthenolide will
deplete intracellular GSH by direct reaction. Our result indicates that in both prostate
cancer and normal prostate cells, GSH level is increased after parthenolide treatment,
especially in the normal prostate cells PrEC. This may be due to the activation of the
Nrf2 pathway, which can induce the transcription of γ-glutamylcysteine synthetase
(GCS), the rate-limiting enzyme in the synthesis of GSH. The Nrf2 activity is regulated
by Kelch-like ECH-associated protein-1 (Keap1). The human Keap1 protein contains 27
cysteines. Nine of them are predicted to have low pKa values and thus relatively high
reactivities [162]. Parthenolide may target these cysteines to activate the Nrf2 pathway
and induce GSH. The Nrf2 pathway [37] is usually downregulated in prostate cancer
compared with normal prostate, which may explain the more remarkable increase of GSH
in normal prostate cells. The dramatic increase of GSH in normal prostate cells may lead
to the protective effect against oxidative stress.
4) Another possibility is that glutathione-S-transferase (GSTs)-mediated parthenolide
metabolism is different in normal and cancer cells. GSTs catalyze the conjugation of
xenobiotics, such as electrophiles, with reduced glutathione. The conjugate is then
transported outside the cells. Parthenolide is an electrophile and may conjugate with GSH
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under the catalysis of GSTs and then be exported outside the cells. Wen et al. found the
basal expression of GST-π is much less in SH-J1 hepatoma cells than in Chang liver cells
[43], which may explain the resistance of Chang liver cells to parthenolide. The
resistance to parthenolide in normal prostate cells may be due to the higher GSTs level in
benign prostate cells compared with prostate cancer cells [36].

The dual role of Akt
Our study found that parthenolide activates the PI3K/Akt pathway as a downstream
event of NADPH oxidase activation. Through phosphorylation, activated Akt mediates
the activation or inhibition of several targets involved in the regulation of cell survival
and death [100]. For example, the phosphorylation and inactivation of the proapoptotic
protein BCL2-antagonist of cell death (BAD) promote cell survival. The phosphorylation
of glycogen synthase kinase 3 (GSK3) inhibits its kinase activity and thus prevents
downstream cyclin D1 phosphorylation and degradation, leading to cell proliferation. Akt
also activates the mammalian target of rapamycin (mTOR) and promotes protein
synthesis. IKK can also be phosphorylated by Akt, leading to the activation of NF-κB
prosurvival pathway. Although parthenolide activates the PI3K/Akt pathway, the NF-κB
pathway is inhibited by parthenolide through direct interaction with IKKβ or p65.
Another important target of Akt is the forkhead (FOXO) family of transcription factors.
The phosphorylation of FOXO by Akt prevents its nuclear localization and target gene
transcription. The FOXO targets include both pro-apoptotic proteins, such as BIM and
FAS ligand, and also the proteins involved in the oxidative stress resistance and DNA
damage repair, such as MnSOD, catalase and GADD45. Therefore, activation of Akt may
promote cell survival by inhibiting the pro-apoptotic target, but also may sensitize cells to
oxidative stress-induced cell death [112] by suppressing stress resistant proteins.
The activation of Akt plays a dual role in the radiosensitization effect of parthenolide.
In chapter two, we showed that PTEN enhances the radiosensitization effect of
parthenolide by keeping the activated p-Akt at a low level and thereby abrogating its
prosurvival function. In chapter three, we showed that Akt mediated FOXO3a
phosphorylation leads to the suppression of antioxidant defense enzymes and contributes
to the radiosensitization effect of parthenolide. In DU145 cells, parthenolide activates
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Akt, even when p-Akt is kept to a relatively low level due to PTEN function, and it
inhibits FOXO3a function and its downstream targets MnSOD and catalase. This
indicates that PTEN cannot prevent parthenolide-induced Akt activation and its function
in sensitizing cells to oxidative stress, but can only inhibit the basal p-Akt level and the
prosurvival role of Akt.
The prosurvival role of the PI3K/Akt pathway is well known. Cancer cells usually
have constitutively active PI3K/Akt and inhibition of the PI3K/Akt pathway has often
been targeted for cancer therapy. However, a recent study shows that in acute
myelogenous leukemia patients, overall survival and relapse-free survival are better in
patients with constitutive PI3K (56% and 72%) than patients without PI3K activation (33%
and 41%) [163], suggesting that constitutive activation of PI3K/Akt can represent a
favorable prognostic factor in cancer patients, consistent with the dual role of Akt.

To summarize, our study demonstrates for the first time that parthenolide can
differentially regulate intracellular redox status in prostate cancer and normal prostate
cells, and selectively sensitize prostate cancer cells to radiation-induced cell death.
Parthenolide modulates cell redox status through multiple mechanisms, including
activation of NADPH oxidase, suppressing NF-κB-, and FOXO3a-dependent expression
of antioxidant enzymes, and altering cellular thiol buffering systems, i.e. GSH and Trx.
To further elucidate how parthenolide regulates intracellular redox ststaus, the effect of
parthenolide on mitochondria function should be studied since mitochondria are an
important source of ROS generation.
The differential effect of parthenolide in cancer and normal cells makes it a promising
agent for sensitizing cancer tissues to the radiation or other oxidative stress-inducing
chemotherapies while protecting normal tissues from oxidative stress-induced damage.
Our preliminary data confirm that the selective radiosensitization effect of parthenolide to
cancer cells is not only observed in prostate cancer, but also in lung cancer (Figure 4.5).
Further studies need to be done to prove whether the selective effect of parthenolide is
cell-type specific. It is also important to test the effect of parthenolide in vivo. Sweeney
et al. [58] reported that, due to its poor solubility, the serum concentration of parthenolide
is 200 nmol/L in mice when given at the maximal attainable dose (40 mg/kg), which is
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much lower than the dose we used in vitro. To improve the serum level of parthenolide, a
water soluble derivative of parthenolide, LC-1 [164] can be used in a future in vivo study.
LC-1 can be metabolized into parthenolide in mice and reach a concentration of more
than 10 µmol/L in plasma, according to our preliminary data (Figure 4.6).
Overall, our data support the concept that increasing oxidative stress in cells with
intrinsically heightened oxidative stress levels leads to cell death while the same stress in
cells with low intrinsic oxidative stress confers adaptive response and cell survival. Thus,
selective enhancement of cancer therapy with oxidative stress- inducing agents is a
possibility and can be particularly effective in cancer cells with high intrinsic oxidative
stress levels.
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Table 4.1 List of FOXO3a target genes detected by real-time
Short Name
CAT
SOD2
PA26
PRDX3
SEPP1
TXNIP
WIP1
FEN1
GADD45A
MLH3
p21
p27

Gene Name
catalase
superoxide dismutase 2
Sestrin-1 (p53-regulated protein PA26)
peroxiredoxin 3
selenoprotein P, plasma, 1
thioredoxin interacting protein
protein phosphatase Wip1
flap structure-specific endonuclease 1
growth arrest and DNA-damage-inducible, alpha
Homo sapiens mutL homolog 3
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
Cyclin-dependent kinase inhibitor 1B (p27Kip1)

probe

67
22
46
62
38
85
25
82
37
67
82
39
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Primer For. (5'->3')
cgcagttcggttctccac
ctggacaaacctcagcccta
gggccgttacccctacatta
agcaaaattattcagcaccagtt
ggagctgccagagtaaagca
acgcttcttctggaagacca
cccatgttctacaccaccagt
accccgaaccaagctttag
agagcagaagaccgaaagga
tcgtttcaccaaaggaatga
cgaagtcagttccttgtggag
ccctagagggcaagtacgagt

Primer Rev. (5'->3')
gggtcccgaactgtgtca
tgatggcttccagcaactc
tcactaagtaggagcactgatgtctt
ccttaaaatagggtgcatgctg
acattgctggggttgtcac
aagctcaaagccgaacttgt
tggtccttagaattcacccttg
gggccacatcagcaattagt
tgactcagggctttgctga
tcatcaaacaggcaataaacttg
catgggttctgacggacat
agtagaactcgggcaagctg

Figure 4.1 Parthenolide suppresses FOXO3a target genes, SOD2, catalase, SEPP1
and FEN1 transcription in prostate cancer cells PC3.
PC3 cells were treated with DMSO or 5 µmol/L parthenolide for 24 hours before
radiation. Cells were collected at 6 hours after 6 Gy radiation and mRNAs were isolated
using TRIZOL reagent (Invitrogen) according to the instructions provided by the
manufacturer. Reverse transcriptase reaction was performed using the SuperscriptTM III
First-Strand synthesis system (Invitrogen) to synthesize template cDNA. Quantitative
real-time PCR was performed using the LightCycler 480 PCR system (Roche). The PCR
primers and matched probes for each gene were designed using Roche Universal Probe
Library software (Applied, Roche). The relative changes of gene expression were
calculated and normalized to GAPDH by using the 2-∆∆Cp method. *p<0.05 compared
with DMSO treated control; #p<0.05 compared with IR treated group.
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Figure 4.2 Parthenolide inhibits radiation induced NF-κB DNA binding activity in
PC3 prostate cancer cells but not in normal prostate PrEC cells.
Cells were treated with DMSO or 5 µmol/L parthenolide for 3 hours before radiation.
Nuclear extracts (NE) were prepared at 6 hours after 6 Gy IR for electrophoretic mobility
shift assay (EMSA) with radiolabelled NF-κB probes. Anti-p50 and anti-p65 antibodies
were used for supershift.
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Figure 4.3 The comparison of basal NF-κB levels in prostate cancer cells DU145,
PC3 and normal prostate PrEC cells.
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Figure 4.4 Normal prostate cells PrEC have higher antioxidant capacity compared
with prostate cancer cells.
A. Comparison of antioxidant enzyme MnSOD and catalase level in three prostate cell
lines.
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Figure 4.5 Parthenolide sensitizes lung cancer cells A549 but not normal lung cells
NL-20 to radiation treatment.
Clonogenic survival assay was performed as described in Materials and Methods in
chapter two. For NL-20 cells, a feeder layer was used for colony formation. To make the
feeder layer, cells were first treated with 30 Gy radiation, which is lethal to the cells, then
plated into the 6- well plates and grew overnight. Cells were then plated on the feeder
layer to form a colony. Briefly, cells were treated with the indicated concentrations of
parthenolide (PN) for 24 hours, and then exposed to indicated doses of radiation. Twentyfour hours after radiation, the media containing PN was removed. Cells were then
maintained for 9 days. The cultures were stained and the colonies containing more than
50 cells were counted. Survival fraction was determined by dividing the plating
efficiency of radiated cultures by the plating efficiency of non-radiated cultures. Values
shown are the means±SD for triplicates.
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Figure 4.6 Pharmacokinetics study of LC-1
Nude mice were injected with LC-1, a water soluble derivative of parthenolide, at the
dose of 40 mg/kg i.p. Then plasma samples were collected at 0.5 hour (3 samples), 1 hour
(3 samples) and 3 hours (3 samples) after injection. Each sample is approximately 500 μl.
The concentrations of LC-1 and parthenolide in the plasma were determined using
LC/MS by the Brunswick Laboratories.
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Appendix: List of abbreviations
AML
AP-1
AR
ARE
ASK-1
ATM
ATP
BAD
BER
CAT
Cys
DBE
2-DG
DMF
DMSO
DPI
Duox
EGFR
ETC
FAD
FAK
Fas
FOXO
GADD45β
GCS
GFP
GPx
GR
Grx
GSH
GSK3
GST
HDAC
4-HNE
HSC
IKC
IKK
IR
JAK
JNK
Keap1
MAPK
2- ME
MM
MnSOD

Acute myelogenous leukemia
Activator protein-1
Androgen receptor
Antioxidant/electrophile response element
Appoptosis signal-regulating kinase 1
Ataxia telangiectasia mutated
Adenosine triphosphate
BCL2-antagonist of cell death
Base excision repair
Catalase
Cysteine
Daf-16 family protein binding element
2-Deoxy-D-glucose
Dose modifying factor
Dimethyl sulfoxide
Diphenylene iodonium
Dual oxidase
Epidermal growth factor receptor
Mitochondria electron transport chain;
Flavin adenine dinucleotide
Focal adhesion kinase
Fibroblast-associated cell surface antigen
Forkhead box class O ranscription factors
Growth arrest and DNA damage-inducing protein β
γ-Glutamylcysteine synthetase
Green fluorescent protein
Glutathione peroxidase
Glutathione reductase
Glutaredoxin
Glutathione
Glycogen synthase kinase 3
Glutathione S-transferase
Histone deacetylase
4-Hydroxynonenal
Hematopoietic stem cells
IκB Kinase complex
IκB kinase
Ionizing radiation
Janus kinase
c-Jun N-terminal kinase
Kelch-like ECH-associated protein-1
Mitogen activated protein kinase
2-Mercaptoethanol
Multiple myeloma
Manganese superoxide dismutase
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MPB
MST1
mTOR
NADPH oxidase
NEM
NF-κB
NIK
NOS
NOX
Noxa1
Noxo1
Nrf2
PDK
PE
PI3K
PIP3
PN
Prx
PSA
PTEN
PTP
Ref-1
RLU
RNS
ROS
RS
SHP-2
SOD
STAT
TCR
TNF-α
TRAIL
Trx
TrxR
TSC2
XIAP
XO

3-(N-maleimido-propionyl) biocytin
Mammalian Ste20-like kinase
Mammalian target of rapamycin
Nicotinamide adenine dinucleotide phosphate oxidase
N-ethylmaleimide
Nuclear factor kappa B
NF-κB-inducing kinase
Nitric oxide synthase
NADPH oxidase
Nox activator 1
Nox organizer 1
Erythroid 2p45 (NF-E2)-related factor 2
Phosphatidylinositol-dependent kinase
Plating efficiency
Phosphatidylinositol 3-kinase
Phosphatidylinositol-3,4,5-trisphosphate
Parthenolide
Peroxiredoxin
Prostate specific antigen
Phosphatase and tensin homologue deleted from chromosome-10
Protein tyrosine phosphatase
Redox factor-1
Relative light unit
Reactive nitrogen species
Reactive oxygen species
Reactive species
Src homology 2 domain (SH2)-containing tyrosine phosphatase 2
Superoxide dismutase
Signal transducer and activator of transcription
T cell receptor
Tumor necrosis factor alpha
Tumor necrosis factor-related apoptosis-inducing ligand
Thioredoxin
Thioredoxin reductase
Tuberous sclerosis complex 2
X-chromosome-linked inhibitor of apoptosis
Xanthine oxidase
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